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ABSTRACT 
 
ASSOCIATIONS AMONG END-OF-LIFE DISCUSSIONS, HEALTHCARE UTILIZATION  
AND COSTS, AND RACE/ETHNICITY IN PERSONS WITH SERIOUS ILLNESS 
Lauren T. Starr, MBE, MS, BA, BSN, RN 
Salimah H. Meghani, PhD, MBE, RN, FAAN 
Acute care near end-of-life (EOL) is associated with lower quality of life and higher EOL costs, 
which are associated with worse quality death. Goals-of-care (GOC) discussions are associated 
with lower costs. Racial/ethnic minorities are less likely to have these discussions. It is unknown 
how costs and healthcare utilization differ by race/ethnicity following inpatient GOC discussion or 
how risk factor profiles are associated with discussion timing. Primary aims included: (1) 
Exploring associations among EOL discussions, costs, and proxies for costs (healthcare 
utilization, place of death) in persons with advanced cancer near EOL (Chapter 2); (2) Assessing 
future acute care costs and healthcare utilization among Whites and African Americans with 
serious illness who either did or did not have inpatient palliative care consultation to discuss GOC 
(“PCC”) (n = 35,154; PCC: n= 1,197; non-PCC: 33,957) (Chapter 3); and (3) Examining risk factor 
profiles associated with timing of PCC before death (PCC 0-14 days before death, n = 612; PCC 
15-60 days before death, n = 292; PCC more than 60 days before death, n = 237) among 
deceased persons who received PCC (Chapter 4). Secondary analysis included demographic, 
clinical, and financial data of patients 18+ admitted to a large, urban, academic medical center 
July 1, 2014 to October 31, 2016. Patients admitted for childbirth or rehabilitation, patients 
hospitalized at the end of the study, and for Chapter 3 patients who died during the admission 
they first received PCC were excluded. A systematic review (Chapter 2) found EOL discussions 
were associated with less acute and intensive care, greater hospice use, and lower EOL costs 
among advanced cancer patients. Propensity score matching (Chapter 3) showed PCC was 
associated with increased discharge to hospice among African American and White patients with 
PCC; and lower 30-day readmissions, fewer future days hospitalized, and lower future acute care 
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costs (average $8,704 per patient) for Whites with PCC, but not African Americans with PCC. 
Multinomial logistic regression and classification and regression tree modeling (Chapter 4) 
showed a complex set of variable interactions were associated with PCC timing before death. 
Results imply need for investment in PCC across racial groups. 
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CHAPTER ONE: INTRODUCTION 
 
Acute care near the end-of-life (EOL) is associated with lower quality of life1 and 80% of 
medical spending in the last year of life.2,3 This spending presents significant challenges to health 
systems tasked with managing costs while providing quality care, and to patients and families 
facing rising out-of-pocket costs. Patient-provider communication about goals-of-care (GOC) or 
EOL planning is associated with lower costs and lower rates of high-cost intensive care near EOL 
among persons with serious illness,2,4-12 with timing of discussion potentially playing a critical role 
in utilization and quality outcomes.12-16 Inpatient conversations occurring 30 days or more before 
death are associated with less aggressive and less costly forms of care than conversations 
occurring close to death,12,15,16 but little is known about risk factors associated with the timing of 
these conversations,17 or how the timing of these conversations is associated with acute care 
costs near EOL. Most studies of GOC/EOL communications and utilization or costs focus on 
patients with cancer and either do not break out outcomes by race/ethnicity or focus on 
predominantly White populations, resulting in a need for more research about these important 
conversations among racial/ethnic minority patients with serious illness. 
Evidence suggests medical costs are significantly higher for racial/ethnic minorities in the 
last six months of life, compared to Whites, and that a significant portion of the higher costs are 
due to greater use of intensive procedures such as mechanical ventilation or intubation and care 
in the intensive care unit (ICU).18 Unfortunately, racial/ethnic minorities are also less likely than 
Whites to have these important care planning conversations.19 Little is known about the 
relationship between initial GOC/EOL discussion during hospitalization and acute care costs 
following discharge from a hospitalization involving these important conversations (hereafter 
called “future acute care costs”) by racial/ethnic group, or how race/ethnicity and the timing of 
these conversations are associated with acute care cost outcomes (see Appendix A).20 To our 
knowledge, no published research has explored the relationship between inpatient palliative care 
consultation (PCC) to discuss GOC (hereafter called “PCC”) during an index admission (defined 
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as the hospital admission during which PCC first occurred in the study period) and future acute 
care costs by race/ethnicity, risk factor profiles associated with the timing of these conversations, 
or descriptions of EOL acute care costs following discharge from a hospitalization with PCC 
(hereafter called “EOL acute care costs”) based on PCC timing. 
To fill these critical gaps, the specific aims of this dissertation are (see Table 1.1): 
Aim 1: To explore associations among advance care planning, costs, and proxies for 
costs (healthcare utilization, place of death) in persons with advanced cancer near EOL using a 
systematic review of published literature (January 2012-January 2019) (Chapter 2).  
Aim 2a: To assess differences in mean future acute care costs and healthcare utilization 
by race/ethnicity among African Americans with PCC, African Americans without PCC, Whites 
with PCC, and Whites without PCC (Chapter 3). 
 Hypothesis 2.1: Mean future acute care costs and utilization will be lower among 
persons who received PCC than persons who did not. 
 Hypothesis 2.2: African Americans who received PCC will have lower mean future acute 
care costs and utilization than African Americans who did not have PCC. 
 Hypothesis 2.3: Whites who received PCC will have lower mean future acute care costs 
and utilization than Whites who did not have PCC. 
Aim 2b: To describe clinical and cost variables for Asian, Hispanic, and other 
racial/ethnic minorities in the dataset.   
Aim 3a: To examine risk factor profiles for PCC patients who died during the study period 
based on the timing of consultation: PCC 0-14 days before death, PCC 15-60 days before death, 
and PCC more than 60 days before death (n = 1,141) (Chapter 4). 
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 Hypothesis 3.1: African American race, younger age, Medicaid use, primary diagnosis of 
condition other than cancer, minor to moderate All-patient refined diagnosis related group (APR-
DRG) Severity of Illness (physiologic decompensation of a patient, see Appendix A), minor to 
moderate APR-DRG Risk of Mortality (likelihood of patient dying, see Appendix A), ICU care 
during index admission, ICU care for more than six days during index admission, and Surgery 
source of referral to palliative care will be associated with PCC close to death (see Appendix A). 
Aim 3b: To describe median EOL acute care costs, discharge to hospice from index 
admission, DNR documentation during index admission, and changes in GOC during index 
admission among deceased patients who received PCC 0-14 days before death, 15-60 days 
before death, and more than 60 days before death (Chapter 4).  
This dissertation study fills critical gaps in the literature (1) by using the innovative 
methodology of stratified propensity score matching among multiple groups to quantifying cost 
savings across hospitalizations associated with PCC in different racial/ethnic populations,7 (2) by 
using state-of-the-art classification tree modeling to examine risk factor profiles for the timing of 
PCC in inpatient settings where late conversations are most likely to occur,17 and (3) by 
describing the EOL acute care costs of deceased patients based on PCC timing. The results of 
our study may be used to help systems manage costs when caring for persons with serious 
illness, including vulnerable patients near EOL. This research contributes to an emerging body of 
literature that explores factors related to racial/ethnic disparities in EOL care and costs. 
Background and Significance 
The High Cost of End-of-Life Care 
 
High financial costs at EOL continue to burden patients, families, and the systems that 
care for them. Growing attention to the cost implications of treatment decisions for patients with 
serious illnesses necessitates research into aspects of care that may modify costs and financial 
burden, while aligning care with patient preferences.1-3 In the United States, 10% of Medicare 
 
 
 
4 
patients account for almost 60% of Medicare annual spending,4,5 with much of the spending 
occurring in the hospital and among persons at EOL.6 According to a 2017 analysis of nine major 
countries, the United States spends an average of $80,000 on patients in the last year of life—
more than any other country studied.7 Acute care contributes to 80% of this medical spending in 
the last year of life.8,9 This higher spending is influenced by Americans’ high use of intensive care 
unit (ICU) and life-prolonging services (e.g., mechanical ventilation, resuscitation, feeding 
tubes).8,9 For example, over 40% of adults 65+ who died of cancer in 2010 received ICU care in 
the last 180 days of life—a figure significantly higher than the 18% reported in other developed 
countries studied.10 In some patient populations, aggressive EOL care has been shown to 
contribute to 43% higher costs than non-aggressive EOL care.11 Despite patient preferences for 
less aggressive inpatient care near death and uncertainty about the value of intensive care at 
EOL, the average number of days patients spent in the ICU during the last six months of life is 
trending up in the United States.12 Most importantly, this high utilization of aggressive treatments 
near EOL may not be consistent with patient preferences and values near EOL,13,14 a critical 
problem.  
Intensive, acute care near EOL is more costly than less intensive care, such as 
hospice,8,15,16 with higher utilization of intensive care resulting in higher costs. For example, one 
study of deceased Americans found the cost of a terminal hospitalization involving care in an ICU 
cost an estimated $38,000 compared to $13,000 if ICU care was not involved.17 High costs at 
EOL are also associated with perceptions of worse quality of death8 and higher decision 
regret18,19 among bereaved families of persons with serious illnesses, providing evidence that 
EOL costs have lasting non-financial effects as well. At the same time, health systems are 
challenged by the cost of inpatient EOL care, especially care in the ICU. With changing payment 
structures and financial penalties for readmissions, hospitals are under increasing pressure to 
manage costs during each hospitalization and across visits.5 More research is needed to better 
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understand how types of care impact costs across hospitalizations in persons with serious illness 
near EOL. 
Goals-of-Care Consultations May Reduce Costs and Intensity of Care 
The purpose of EOL and care planning conversations is to help clarify patients’ 
preferences about treatment and care and ensure the care patients receive is consistent with 
their expressed preferences.20,21 Patient-provider conversations about goals and end-of-life 
include discussion about prognosis, treatment options, and aspects of both living and dying that 
clarify patients’ goals, values, priorities, and preferences.22 As intended, these discussions are 
associated with patients receiving EOL care consistent with expressed preferences.23,24 These 
discussions are also associated with less aggressive treatment5,8,19,25-32 and lower acute care 
costs among persons with serious illness.5,8  
About seven in ten PCCs include these important GOC discussions.5,33 By promoting 
clear communication about prognosis and patient preferences, PCC has been shown to provide 
care consistent with patient goals, improve satisfaction, reduce overall and ICU healthcare 
utilization, reduce use of laboratory testing and other ancillary services, and significantly lower 
hospital costs (9%-25% less) and pharmacy costs compared to usual care in hospital settings.5,26-
31,34-38 Among persons with advanced cancer, for example, these cost savings are even greater 
when a patient has other serious diseases/multiple comorbidities.5,39 In some populations, PCC is 
even associated with a doubling of inpatient and outpatient hospice enrollment,40 contributing to 
reductions in EOL costs. As May and colleagues conclude in their 2014 meta-review of palliative 
care’s effect on costs, inpatient PCC programs provide better care to patients with serious 
illnesses and save hospitals money.27 More research is needed to better understand how PCC 
involving GOC/EOL discussions influence healthcare costs and utilization across hospitalizations 
for persons with serious illness.5 
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The 2017 propensity-matched parent study of these data (n = 41,363) found statistically 
significant reductions in future acute care utilization and future acute care costs after patients 
received PCC.5 Specifically, average future acute care costs were found to be more than $6,000 
lower in patients who received PCC following initial hospitalization.5 Patients who received PCC 
were less likely to incur “any future acute care cost” during a future hospitalization, had lower 30-
day readmission rates, fewer average number of days in the hospital post-discharge, and fewer 
average number of days in the ICU post-discharge.5  
One study that examined relationships between EOL discussions and EOL costs found 
direct costs in the last seven days of life to be 36% lower for patients who reported having EOL 
discussions about care preferences with their physicians compared to patients who did not have 
GOC/EOL conversations.8 This 2009 study estimated costs using national per capita healthcare 
data tied to healthcare utilization, and featured data from 2004, which underscores the need for 
more current studies of healthcare utilization, actual costs, and EOL discussions among persons 
with serious illnesses. This study also analyzed outcomes of patients with cancer, highlighting the 
need for more research in persons with other serious illnesses, and similarly did not address the 
variable of race/ethnicity.  
Finally, self-reported discussion with a physician about EOL care has also been found to 
be associated with lower direct costs of care in the last week of life, but authors focused 
exclusively on decedents with cancer, used estimated costs based on utilization and not actual 
cost data, and failed to report data on the association.1 This study also underscores the need for 
actual costs outcomes research on a broader patient population and set of variables. Our study 
aims to address this need by providing actual direct cost data (see Appendix A for table of 
variables) for White and African American adults with serious illnesses. 
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Advance Care Planning 
Advance care planning (ACP) is a process that includes discussing and documenting 
patient preferences about GOC for patients who may lose capacity or the ability to communicate 
preferences in the future.41 It includes GOC conversations and may include discussion about 
EOL, and sometimes but not always occurs during PCC.24,41 Existing studies define ACP 
discussions differently,41 with some focused broadly on EOL care conversations32,42-45 or GOC 
conversations,46,47 while other studies focus more narrowly on hospice discussions48 or a 
combination of advance directives, Physician Orders for Life-Sustaining Treatment (POLST) 
orders, or do-not-resuscitate (DNR) or do-not-intubate (DNI) orders49-52 (See Table 1.2 for 
definitions of terms). One study, for example, used a broad definition of ACP by studying PCC 
and any component of ACP—defined as any GOC discussion, advance directive, POLST order, 
or DNR/DNI order.52 Just as little is known how GOC/EOL discussions relate to acute care 
utilization and costs near EOL, evidence about associations between ACP, these outcomes, and 
race/ethnicity is also limited. One recent study of case-control matched decedents found patients 
who had ACP had fewer inpatient admissions and inpatient days before death, and a $9,500 
reduction in Medicare costs compared to patients who did not have ACP,53 but gaps in cost 
analysis persist. In this dissertation, we systematically review the available literature to identify 
and address research gaps related to EOL communication and costs. 
Timing of Goals-of-Care Conversations May Influence Costs and Intensity of Care 
Although PCC benefits patients, the timing of these conversations also matters. If 
GOC/EOL discussions occur too close to death, patients and families may make pressured 
decisions leading to care that is not concordant with preferences.20,32,54 In one study of advanced 
heart failure patients, PCC during terminal hospital admission was often either absent or very 
near death, with a median time of six days between PCC and death and only 24 hours between 
orders for comfort care and death.55 One study found the median days between referral to PCC 
and death was 10 days for patients with chronic obstructive pulmonary disease, 12 days for 
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patients with heart failure, 14 days for patients with severe dementia, and 20 days for patients 
with cancer,56 but it is unknown at what point, if at all, GOC were discussed. However, each 
additional day from hospital admission to GOC conversation was found to be associated with a 
4% increased risk of aggressive interventions and in-hospital death, and 19% greater odds of ICU 
admission.57 In many cases, patients may not receive the benefits of comfort care as early as 
they might have liked, possibly resulting in greater regret about care decisions.19 
Evidence suggests the majority of early PCCs (90 or more days before patient death) 
occur in outpatient settings (84%) and the majority of late PCCs (less than 90 days before patient 
death) occur in inpatient hospital settings (82%),7 making it important to understand risk factors 
associated with the timing of PCC in hospital settings where late conversations are more likely to 
occur.58 Earlier PCC is associated with lower rates of inpatient care, ICU care, and emergency 
department utilization in the last month of life; and lower inpatient and outpatient costs in the last 
six months of life compared to persons receiving late palliative care less than 90 days before 
death.58,59 Earlier PCC is also associated with greater family satisfaction with care, as well.60 
Family members of veterans whose first PCC occurred 91-180 days before death, for example, 
were more likely to rate their loved one’s care as excellent compared to families of veterans 
whose PCC occurred 0-7 days before death (adjusted odds ratio = 1.37).60 In this study, PCCs 
that took place more than one month before death were associated with higher ratings of 
emotional and spiritual support, and respectful care and communication.60  
In the literature, “early” GOC discussions are defined inconsistently.32,43,57,61,62 Some 
studies define “early” as occurring more than 30 days before patient death.32,43 One study defined 
“early” as a GOC conversation occurring in the first month following diagnosis.42 In contrast, 
another study generalized late timing to be when a patient had lost decisional capacity following 
hospital admission (requiring surrogate involvement).62 In this case, the author implied late timing 
is actually too late. Despite differences in definition, it is important to understand outcomes 
associated with the timing of early and late inpatient GOC discussions. 
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Inpatient GOC discussions occurring 30 or more days before death are associated with 
less intensive healthcare utilization near EOL and greater quality of life than conversations 
occurring less than 30 days before death.32,61 For example, Mack et al. found evidence that 
patients with advanced cancer who had EOL discussions more than 30 days before death were 
less likely to receive aggressive EOL care, acute care in the last 30 days of life, and 
chemotherapy in the last seven days of life; and were more likely to receive hospice care.32 
Ahuluwalia et al. found EOL care planning discussion in the first month following cancer diagnosis 
was associated with a lower likelihood of receiving acute care at EOL among veterans with 
advanced cancer.42 Although evidence on GOC timing in cancer populations is growing, evidence 
is limited among patients with other serious illnesses. Our study aims to meet that need by 
assessing a broad population of persons with serious illness. 
In addition, little is known about risk factors and risk factor profiles associated with the 
timing of GOC conversations in inpatient settings. To our knowledge, no known studies have 
assessed risk factors or the interaction of risk factors associated with time between PCC and 
death, or whether race/ethnicity is associated with the timing of inpatient PCC. Our study aims to 
address this gap by identifying risk factor profiles of patients based on the timing of consultation 
before death (PCC 0-14 days before death, PCC 15-60 days before death, and PCC more than 
60 days before death). By exploring the relationship between the timing of PCC and EOL acute 
care costs, our study also aims to contribute to an emerging body of literature about the timing of 
inpatient communications and costs near EOL in patients with serious illness. 
Racial/Ethnic Disparities in Goals-of-Care Discussions and End-of-Life Costs 
Unfortunately, racial/ethnic minorities with serious illness in the United States are less 
likely than White persons with the same illnesses to have these important EOL discussions with 
healthcare providers and non-providers, such as family members.63-68 As one recent study 
concluded, most racial and ethnic minorities with a serious illness have not talked with anyone 
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about their goals, values, or care preferences—a difference that may result in lower quality 
care.63 This difference is unnecessary given that most racial minorities think doctors should 
discuss EOL care issues with patients [82% of African American adults, 83% of Hispanic adults, 
and 82% adults self-reporting as “Other” (compared to 87% of White adults)].63 
Although research suggests health literacy, rather than race, predicts EOL 
preferences69,70 and that communication-based interventions can influence these preferences,69,71 
African Americans are more likely than Whites to receive life-prolonging care in the last few days 
of life72 and aggressive care at the end-of-life,68,73,74 and are less likely to complete advance 
directives68,72,75-77 or receive hospice care.73,75 Compared to Whites, racial/ethnic minorities 
experience less ACP63,78,79 and receive more intensive EOL care.63,78,80-84  
Higher End-of-Life Costs among Racial/Ethnic Minorities 
This higher use of intensive care contributes to greater costs for minorities near EOL. 
One large study (n = 158,780) of Medicare data found that in the last six months of life, medical 
costs were 32% higher for African Americans and 57% higher for Hispanics compared to Whites; 
and that about 40% of the higher costs for Non-Whites were due to greater use of intensive 
procedures (e.g., gastrostomies) and ICU hospitalization.80 (Differences in age, sex, cause of 
death, morbidity burden, hospice use, and other variables accounted for the other differences in 
higher EOL costs for minority patients.80) African Americans and Hispanics were more likely to die 
in hospitals compared to Whites,80 also contributing to differences in costs. Across 
races/ethnicities, expenditure dramatically increased in the last month of life, with Hispanics 
receiving the most costly care of any racial/ethnic group studied ($13,900 compared to Whites, 
whose expenditure averaged $8,900 in the last month of life).80 These racial/ethnic disparities in 
ACP, EOL care, and EOL costs are concerning, and have prompted the National Academy of 
Medicine to call for more research on the subject.24  
 
 
 
11 
Innovation 
The study is innovative in a number of ways. First, it fills gaps in the literature relevant to 
the care of persons with serious illnesses. Second, stratified propensity score matching is a 
robust, innovative method for exploring PCC, race/ethnicity, and cost outcomes. Similarly, 
classification tree modeling is an effective, novel way to identify associations between risk factor 
profiles (the interaction of risk factor variables) and the timing of PCC. Finally, study findings may 
further underscore the need for timely GOC and EOL discussions (hereafter called “EOL 
discussions”) for patients with serious illness. Clinicians may use the results of our study to 
identify persons with risk factors for having EOL conversations close to death, then initiate those 
conversations earlier to help reduce disparities and enable EOL care consistent with preferences.  
Goals-of-Care/End-of-Life Communications, Utilization, and Costs  
Little is known about the relationship between EOL discussions and acute care utilization 
and costs across hospitalizations among racial/ethnic groups with serious illnesses.61 The parent 
study of this dissertation research found future acute care costs to be significantly higher among 
persons with serious illnesses who did not receive PCC, compared to similar patients who had 
received PCC;5 and that consultations involving GOC discussions may decrease future 
healthcare utilization and costs beyond initial hospitalization.5 While most available research on 
EOL conversations and EOL costs focuses on healthcare utilization, not actual costs (see 
Appendix A),61 or predominantly on the cancer population, no published research analyzes EOL 
communications, acute care utilization and costs, and race/ethnicity.61 In fact, most available 
research on racial/ethnic disparities in EOL discussions focuses on advance directive 
completion,63,85 documents that do not always include preferences for EOL care (see Table 1.2 
for description of terms) and alone may not facilitate care consistent with patient goals.63,86 This 
dissertation research will explore race/ethnicity beyond the limited scope of advance directives by 
focusing on GOC discussions, which are more likely to result in EOL care concordant with patient 
values, goals, and wishes.24 
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Timing of Goals-of-Care and End-of-Life Discussions 
Evidence about demographic, clinical, and financial risk factors associated with the timing 
of GOC discussions among adults with serious illness prior to death is very limited61 (see Table 
1.1, Appendix A). Although a small number of studies have assessed associations between 
healthcare utilization and the timing of EOL discussions,32,42,43,57,62 they have generally focused 
on decedents with cancer and have not analyzed race/ethnicity or cost outcomes. It is unknown 
what variables are associated with the timing of consultations for EOL care planning. Because 
GOC and EOL discussions near death are associated with more aggressive interventions, ICU 
care, and death in the hospital,32,42,43,57,61,62 it is important that clinicians be aware of factors 
associated with later EOL conversations to reduce any disparities in EOL communication and 
care. End-of-life acute care costs associated with the timing of such discussions are also 
unknown. And because high medical costs at EOL are associated with worse quality death 
among persons with serious illness,8 it is ethically imperative that risk factor profiles associated 
with the timing of these discussions be explored. 
Parent Study Dataset for Secondary Analyses 
The parent study of this dissertation research (n = 41,363 patients) was conducted at a 
776-bed, urban, academic medical center in the Northeast region.5 The medical center is located 
in a racially, ethnically, and socioeconomically diverse city and service area. African Americans 
represent the largest racial or ethnic group (46%) in the medical center’s service area 
population—Whites represent 36%, Asians 9%, and Hispanics 6%.87 The majority (84%) of 
residents in the medical center’s service area speak English at home, with translation services 
available for the 4% who speak Spanish at home and the 7% who speak an Asian language.87  
Less than half (49%) of residents age 25+ in the service area graduated from high school,87 
possibly influencing health literacy. In addition, a majority of families (53%) in the medical center’s 
service area live in poverty, suggesting diversity in the dataset’s socioeconomic representation.87 
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Finally, across the medical center’s service area, one in four adults 60+ are in fair or poor 
health.87 
The purpose of the parent study was to compare future acute care costs across 
hospitalizations following PCC between patients who had PCC (n = 1,853) and a propensity-
matched cohort of patients who did not (n = 39,510). The study found PCC was associated with 
reductions in intensive care and other acute care utilization, and a mean cost-savings of over 
$6,000 per patient.5  
Study data include admissions of patients age 18 and older who were admitted to the 
medical center between July 1, 2014 and October 31, 2016. To assess a population of patients 
with serious illness, patients were excluded if they had been admitted for childbirth or 
rehabilitation. Patients who died during index admission (the admission during which the first 
PCC occurred within the study period, see Appendix A) or whose discharge information was 
unknown (i.e., patients still hospitalized at the end of the study period) were excluded. The 
medical center’s palliative care registry was then used to identify patients who received PCC 
specifically to discuss GOC, according to records indicating the reason for each PCC. Patients 
who exclusively received PCC for reasons other than GOC (e.g., pain management, spiritual 
distress, transition planning) were excluded to enable cleaner assessment of associations 
between GOC discussions, utilization, and costs. The medical center’s cost accounting system 
(McKesson Health Solutions, King of Prussia, PA) was then used to track acute care utilization 
and direct costs (see Appendix A) forward after the index admission through the end of the study 
period (“future acute care costs”).5 According to the parent study, direct costs represent the best 
estimate of the actual cost of providing hospital services including nursing labor, other allied 
health professional labor, pharmaceuticals, supplies, procedures, and testing.5 Utilization and 
costs incurred during the index admission were excluded.  
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The medical center’s palliative care team, which primarily operates as a consultation 
service, includes physicians, advance practice nurses, registered nurses, social workers, a 
pharmacist, and a chaplain.5 Managed by a nurse coordinator, the palliative care registry includes 
demographic and clinical information. The parent dataset ties these data to the utilization and 
financial data available from the cost accounting system. 
Chapter Aims and Rationale 
The aims of this three article for publication dissertation research are to: (Aim 1) Explore 
associations among ACP, costs, and proxies for costs (healthcare utilization, place of death) in 
persons with advanced cancer near EOL (Chapter 2); (Aim 2) (a) Assess future acute care costs 
and healthcare utilization among Whites and African Americans with serious illness who either do 
or do not have PCC (Chapter 3) and (b) describe PCC patients across racial/ethnic groups using 
cost and utilization variables, including discharge to hospice, DNR documentation, and changes 
in GOC; and (Aim 3) (a) Examine risk factor profiles associated with the timing of PCC before 
death (0-14 days before death, 15-60 days before death, more than 60 days before death) among 
deceased persons with serious illness, and (b) Describe median EOL acute care costs, discharge 
to hospice, DNR documentation, and changes in GOC based on PCC timing (Chapter 4). 
Chapter 2 
Aim. Chapter 2 presents a systematic review of published literature (January 2012-January 2019) 
describing associations between ACP/EOL discussions in persons with advanced cancer and 
financial costs and proxies for cost, such as healthcare utilization and place of death, near EOL. 
We chose to focus the review on persons with advanced cancer because half of patients with 
advanced cancer receive aggressive treatment within the last month of life.32 Evidence suggests 
aggressive EOL care among persons with advanced cancer contributes to 43% higher costs than 
cancer care managed non-aggressively at EOL.11 Given that cancer is one of the most expensive 
conditions to treat,88 it made sense to focus on this important population. In addition, most 
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research on GOC/EOL discussions explores associations in the cancer population, limiting our 
opportunity to review studies of associations between ACP and costs in a broader population of 
persons with serious illness.  
Rationale. The systematic review identified only three studies with cost outcomes, two of which 
were based on the same dataset. The review did not find any studies that assessed EOL 
communications and costs in the context of race/ethnicity. Finally, the review identified six studies 
related to the timing of ACP/GOC conversations, but none of the studies examined factors 
associated with the timing of GOC or EOL conversations—associations we will explore in this 
dissertation. Although consistent with the published literature, our Chapter 2 (systematic review) 
focuses on persons with advanced cancer, we will apply our findings to a broader population of 
persons with serious illnesses in Chapters 3 and 4.  
Chapter 3 
Aim. Chapter 3 describes a secondary analysis of a retrospective cohort study conducted at a 
large, urban, academic medical center in the Northeast region (n = 41,363). The goal is to 
understand if there is a difference in mean future acute care costs and healthcare utilization 
among the following subgroups of persons with serious illness: African Americans with PCC, 
African Americans without PCC, Whites with PCC, and Whites without PCC. Asian, Hispanic, and 
other racial/ethnic minorities in the dataset will also be described; as will DNR documentation 
during index admission and, for PCC patients, changes in GOC during index admission.   
Rationale. Compared to Whites, racial/ethnic minorities experience less ACP/GOC 
planning,63,78,79 receive more intensive EOL care,63,78,80-84 and incur higher medical costs in the 
last six months of life.80 High medical costs at EOL are associated with worse quality death.8,89 
Although PCC is associated with significantly lower hospital costs and utilization of acute 
care,5,27,29,34-38 no published research explores associations between race/ethnicity and costs or 
utilization in the context of PCC.  The parent study did not assess costs or utilization by 
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race/ethnicity, so it is unknown how race/ethnicity influences future acute care costs and 
utilization following PCC. 
Chapter 4 
Aim. Chapter 4 describes a secondary analysis of deceased patients who received PCC at a 
large, urban, academic medical center in the Northeast region (n = 1,141), supplemented by new 
data (Medicaid status and days between PCC and death) pulled from electronic medical records. 
The goals of this study are to: (a) examine risk factor profiles for PCC patients who died during 
the study period based on the timing of consultation: PCC 0-14 days before death, PCC 15-60 
days before death, and PCC more than 60 days before death; and (b) describe median EOL 
acute care costs, discharge to hospice, DNR documentation, and changes in GOC by PCC 
timing. 
Rationale. Goals-of-care conversations occurring more than 30 days before death are associated 
with less intensive healthcare utilization near EOL and greater quality of life32,61 and use of 
hospice,32 supporting the idea that time enables patients and families to make informed decisions 
possibly more consistent with preferences for less intensive care near EOL. Evidence suggests 
many patients who have GOC discussions with their providers have these conversations close to 
death,32,42,43,62,90 typically in inpatient settings following a change in health resulting in 
hospitalization.58 Racial/ethnic minorities are less likely to receive GOC discussions,63,78,79 but 
among those who do have these conversations with providers it is unknown how close to death 
the conversations occur. In fact, despite the well-established relationship between GOC 
discussion timing and healthcare utilization and costs, little is known about patient and clinical risk 
factors associated with the timing of PCC conversations before death. Understanding risk factor 
profiles and EOL costs associated with the timing of discussions may contribute to developing 
clinical decision tools and encourage clinicians to have timely GOC discussions with patients. 
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CHAPTER TWO: ASSOCIATIONS AMONG END-OF-LIFE DISCUSSIONS, 
HEALTHCARE UTILIZATION, AND COSTS IN PERSONS WITH ADVANCED 
CANCER: A SYSTEMATIC REVIEW 
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Abstract 
 
Background: Aggressive end-of-life (EOL) care is associated with lower quality of life and 
greater regret about treatment decisions. Higher EOL costs are also associated with lower quality 
EOL care. Advance care planning and goals-of-care conversations (“EOL discussions”) may 
influence EOL health-care utilization and costs among persons with cancer. 
Objective: To describe associations among EOL discussions, health-care utilization and place of 
death, and costs in persons with advanced cancer and explore variation in study measures. 
Methods: A systematic review was conducted using PubMed, Embase, and CINAHL. Twenty 
quantitative studies published between January 2012 and January 2019 were included. 
Results: End-of-life discussions are associated with lower health-care costs in the last 30 days of 
life (median US$1048 vs US$23482; P < .001); lower likelihood of acute care at EOL (odds ratio 
[(OR] ranging 0.43-0.69); lower likelihood of intensive care at EOL (ORs ranging 0.26-0.68); lower 
odds of chemotherapy near death (ORs 0.41, 0.57); lower odds of emergency department use 
and shorter length of hospital stay; greater use of hospice (ORs ranging 1.79 to 6.88); and 
greater likelihood of death outside the hospital. Earlier EOL discussions (30. days before death) 
are more strongly associated with less aggressive care outcomes than conversations occurring 
near death. 
Conclusions: End-of-life discussions are associated with less aggressive, less costly EOL care. 
Clinicians should initiate these discussions with patients having cancer earlier to better align care. 
with preferences. 
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Background and Significance 
 Aggressive, life-sustaining end-of-life (EOL) care is associated with lower quality of life,1 
family perceptions of lower quality of care,2,3 and greater regret about treatment decisions.4 It is 
also more costly.5-7 In one study, cancer patients who received aggressive EOL care incurred 
43% higher costs than patients who received non-aggressive care.8 High costs near EOL, which 
are a proxy for more acute care, are associated with worse quality of death6 and may contribute 
to patients’ financial toxicity, the financial burden and stress caused by cancer that is associated 
with myriad negative clinical and quality outcomes.9-13 High costs also create hardship for 
families, one-third of whom report spending all or most of their savings on costs related to their 
loved one’s terminal cancer care,14 and for health systems tasked with managing costs while 
providing high-quality care.15 Most importantly, costly aggressive care may not always reflect 
patient preferences.4 To better align care with preferences, the National Academy Medicine and 
American Society of Clinical Oncology recommend patients and providers have goals-of-care 
(GOC) conversations16 and that palliative care, which typically involves such discussions,15 be 
integrated into standard oncology care.17 These conversations may include discussions about 
patient values, prognosis, treatment options, aspects of living and dying, or specific interventions 
a patient may want if certain future conditions occur—all of which may occur in advance care 
planning (ACP).18 Interventions that include communication about ACP and care preferences 
have been found to improve concordance between care preferences and actual care delivered.19  
Given that the costs of cancer care may vary by diagnosis, stage of disease, and 
treatment options;20 and that cancer disproportionately burdens racial minorities, who are often 
diagnosed at later stages when treatment may be very expensive,20,21 it is important to 
understand how care planning conversations are associated with healthcare utilization and costs 
among persons with advance-stage cancer, when utilization and costs may increase.20 Evidence 
suggests patient-provider discussions about EOL preferences are associated with less 
aggressive treatment near death6,22,23 and that interventions involving GOC discussions may 
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reduce costs.24,25 Cancer is the second leading cause of mortality in the United States and 
globally,26,27 and one of the most expensive diseases to treat,28 in part due to rapid (often 
expensive) advances in cancer science that are adopted as standard of care. Although reviews of 
ACP and costs among older adults exist,29,30 variables and patient populations vary, limiting 
conclusions and warranting separate analysis among patients with cancer. The purpose of this 
review is to explore associations among ACP/GOC/EOL discussions, hereafter called “EOL 
discussions,” healthcare utilization, and costs among persons with advanced cancer (Stage III+) 
or persons who died of cancer. This review will also assess consistency and variation in how 
studies define EOL discussions and measure healthcare utilization outcomes.  
Methods 
 Literature search strategy. Authors used PubMed, Embase, and CINAHL databases to 
find studies conducted in the United States published from January 1, 2012 to January 8, 2019 
that explored relationships between EOL discussions and financial costs, healthcare utilization, or 
place of death in adults with advanced cancer (see Table 1 for search terms). Because 
healthcare payment schemes differ by country, resulting in different costs and ways to measure 
costs, studies outside the United States were excluded. Qualitative studies, studies of children or 
adolescents, and studies presented at meetings or as abstracts were excluded. To enable 
comparability of costs and utilization near EOL, studies of patients with primarily early-stage 
cancer were excluded unless they focused on EOL care. The authors screened titles in search 
results and selected abstracts for review. Data extracted from each study were organized in a 
table of evidence summarizing key characteristics and study quality (Table 2). The review 
followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
recommendations.31 Two authors independently rated the quality of evidence using the Oxford 
Centre for Evidence-based Medicine grading guide.32 
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Results 
Literature search. Systematic searches resulted in 2,911 unduplicated articles. Twenty-
three additional articles were identified through references and search engine recommendations 
(Figure 1). After identifying relevant titles in each database and importing those listings into 
EndNote software, 236 unduplicated abstracts were reviewed. Based on review criteria, 20 
studies were included. 
Description of studies. Included studies were conducted with populations 
predominantly composed of patients with Stage III or IV cancer, or patients who recently died 
from cancer. Cancer types included breast,33 hematological,34,35 gynecological,1,36,37 lung or GI,38 
and any type.23,39-50 Sample sizes ranged from 84 to 2,752 participants, with a median of 226 
participants per study. Two studies featured fewer than 100 participants.36,40 All studies were 
conducted in the United States. Settings varied and included for-profit, not-for-profit, and 
government institutions. Some hospital-based studies incorporated data from outpatient care. The 
studies’ comparator was an EOL discussion, defined as any conversation about EOL goals or 
treatment preferences with a healthcare provider or trained facilitator, documented in medical 
records or self-reported by patients or surrogates, or described as ACP, which sometimes 
includes advance directives (AD), physician orders for life-sustaining treatment (POLST), or do-
not-resuscitate (DNR) or do-not-intubate (DNI) orders that suggest discussion about preferences. 
Because ADs, POLSTs, and DNR documentation may be associated with preference for 
treatment limitations,41,51 results of studies that exclusively or predominantly assessed ADs, 
POLSTs, or DNR were differentiated. Three studies examined EOL costs using either EOL 
discussion or a proxy such as AD as comparator.41,42,50 No studies examined the impact of out-of-
pocket costs on patients. Eighteen studies assessed relationships between EOL discussions and 
healthcare utilization near death1,23,33,35-38,40,43-50,52 and six studies assessed place of death.1,33-
35,37,44 In addition, six studies incorporated elements of time in their assessment of EOL 
discussions, generally referring to these discussions as early (31+ days before death) or late 
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(within 30 days of death), with later conversations typically occurring in inpatient 
settings.1,23,39,47,49   
Quality of Studies. To assess study quality, two authors (L.T.S. and K.L.C.) 
independently used the Oxford Centre for Evidence-based Medicine Levels of Evidence grading 
guide.32 Independent ratings were then compared. Disagreements on ratings (10% of studies) 
were resolved by further analyzing study methodology. One study was a retrospective analysis of 
a randomized clinical trial (RCT);50 one study was non-randomized, intervention-based;45 and 18 
studies were observational.1,23,33,35-38,40-44,46-49,52,53 Strengths of the studies included clearly-stated 
objectives and inclusion criteria, sample sizes adequate for meeting objectives, and well-defined 
outcomes and variables (Table 2). Study limitations included prevalence of retrospective cohort 
design; variation among independent variable measurement, with some studies assessing EOL 
discussions based on self-report and others based on medical chart review; diversity in outcomes 
measured; and small sample size for two studies,36,40 limiting power and analysis (Table 2). Six 
studies received lower ratings because they did not account for confounders.1,37,40,44,47,49   
Summary of Findings.  
EOL discussion associated with lower EOL costs. Only three studies (two from the same 
dataset) measured costs,41,42,50 but one of these studies was a high-quality RCT.50 In their RCT, 
Patel and colleagues found patients with advanced cancer who received a six-month program to 
discuss and document EOL preferences with a trained lay health worker, and who later died 
(n=120), had lower total healthcare costs within 30 days of death (median [interquartile range], 
$1,048 [$331-$8,522] vs. $23,482 [$9,708-$55,648]; p < .001) than patients in the control group 
who died.50 Fifteen months after randomization, total healthcare costs among the entire study 
population were lower in the intervention group, but the difference was not statistically significant 
(median [interquartile range], $86,025 [$63,255-$133,256] vs. $111,958 [$75,803-$171,025]; p = 
.08).50  
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The two studies by Garrido and colleagues41,42 are limited in their applicability due to how 
authors defined and used EOL communications as variables. In their 2015 study, the authors 
assessed costs in the last week of life in terms of preferences for heroic treatment or no heroic 
treatment, as documented in ADs.41 As expected, costs were lower among patients who reported 
a preference for no heroic measures at EOL (adjusted mean incremental effect = - $3,082, p = 
0.03) compared to patients who preferred heroic measures.41 Because AD completion was 
associated with a difference in EOL care preferences, the authors’ results may be biased toward 
lower costs, limiting comparison to the RCT by Patel and colleagues. The other study by Garrido 
and colleagues claimed a self-reported EOL discussion with a doctor about EOL care preferences 
was significantly associated with costs in the last week of life (p = 0.001), but failed to provide 
cost data, limiting comparison.42 
EOL discussion associated with less acute care near EOL. Despite variations in 
discussion comparators, we found each study in the review identified some, if not many, 
significant associations between EOL discussion and either lower costs near EOL,41,42,50 lower 
utilization of high cost care such as acute or intensive care,1,36-40,43,46,47,50 or reduced use or 
duration of hospital services.1,36,38,45,47,49,50 Studies of EOL or GOC discussions not involving ADs 
or POLST found associations between these discussions and a lower likelihood of having acute 
care in the last 30 days of life [Odds Ratios (OR) ranging 0.43 to 0.69)23,39,45,50 and a lower 
likelihood of receiving ICU care in the last 30 days of life (ORs 0.26 and 0.68),45,46 with 
insignificant results suggesting trends toward lower utilization. Patients who complete ADs may 
be more likely to prefer less intensive EOL care,41 but Cappell and colleagues (n=422) found 
similar odds: patients with an AD were similarly less likely to receive ICU care within 30 days of 
death (25% vs. 40%, OR 0.49, p = 0.001) than patients without ADs.35  
Studies did not consistently measure readmission rates, emergency department visits, or 
length of stay, although those that did often found associations with reduced rates.36,45,47,50 For 
example, Rocque and colleagues (n = 2,752) found patients who started or completed an ACP 
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discussion about care goals and preferences with a lay facilitator trained in the Respecting 
Choices method had lower hospitalization rates within 30 days of death (46% vs. 56%, p = 0.02) 
and that patients with ACP discussions had lower Emergency Department (ED) visit rates within 
14 days of death (33% vs. 42%, p = 0.04).45 In their RCT, Patel and colleagues found patients 
who received a structured ACP program involving GOC or care preference discussion before 
death were also less likely to visit the ED (5% vs. 45%, p < 0.001) or be hospitalized (5% vs. 
43%, p < 0.001) in the last 30 days of life compared to the control group (n = 120 total deceased 
patients), and had fewer mean ED visits (p < 0.001) and fewer mean admissions (p < 0.001) in 
the last 30 days of life.50 Hoerger and colleagues (n = 125 deceased patients) similarly found that 
palliative care visits to discuss treatment decisions were associated with a lower odds of 
hospitalization within the last 60 days of life (OR 0.62, p = .005).38 In total, four studies found 
evidence of reduced hospital length of stay (LOS), as well.36,47,49,50  
The six studies that assessed place of death found associations between EOL discussion 
and death outside a hospital, but generally used mixed definitions of ACP as the comparator.1,33-
35,37,44 Eckhert and colleagues (n = 163), who broadly defined an EOL discussion as an outpatient 
GOC discussion, AD, POLST, or DNR/DNI more than 30 days before death, found patients with 
ACP were more likely to die in hospice than the ICU (p = 0.001) or in a non-ICU acute care 
setting (p = 0.004).34 Conceptualizing EOL discussion to also include ACP, GOC, and discussion 
proxies such as POLSTs and ADs, Zakhour and colleagues (n = 136) found patients who had a 
discussion inpatient had much higher odds of dying in the hospital than patients who had a 
discussion outpatient (34% vs. 0%, OR 20.5, 95% CI, 1.19 to 352.6, p = 0.04), providing context 
to possible relationships between discussion location and place of death.37 In this study, 70% of 
patients had a GOC discussion, suggesting the findings may compare to studies with GOC as a 
comparator.37 Studies that assessed place of death among patients who had ADs or POLST 
found similar results. For example, Cappell and colleagues found patients with ADs were less 
likely to die in the ICU and more likely to die at home (p = 0.003).35 Pedraza and colleagues (n = 
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2,159) found the odds of dying outside the hospital were more than two times greater for patients 
with POLSTs than patients with ADs (OR 2.3, p < 0.001).54   
Of the 11 studies that assessed hospice use, nine studies found significant associations 
with EOL discussions (ORs ranging 1.79 to 6.88).23,33,34,37,38,40,44,48 Findings were strongest among 
studies that defined discussions based on EOL, GOC, and treatment preference 
conversations.23,33,38,40,48 Among patients who died during the RCT (n = 120), for example, Patel 
and colleagues found an GOC intervention was associated with higher rates of hospice use (48% 
vs. 77%, p = 0.002; OR 3.51, 95% CI 1.6-7.69, p = 0.002).50 Mack and colleagues (n = 1,231) 
also found patients who had EOL discussions were much more likely to receive hospice care (OR 
6.88, 95% CI 4.36-10.8, p<0.001),23 as did Gramling and colleagues (n = 231), who found 
patients engaged in a length-of-life discussion were more likely to enroll in hospice by six-month 
follow-up (OR = 2.16; 95% CI 1.25–3.73).48 The two studies that defined EOL discussions based 
on a mix of GOC, ADs, and POLST use also found significant results.34,37 Zakhour and 
colleagues, for example, found patients who had a conversation involving GOC, AD, or POLST 
31+ days before death were more likely to have higher rates of hospice (p = 0.001) and more 
days in hospice (p < 0.001).37 Adding context to these findings, Pedraza and colleagues found 
patients with POLST were more likely than patients with ADs to enroll in hospice (OR 2.69, 95% 
CI 2.25 to 3.22, p < 0.0001).44 Two other studies that measured hospice use did not find 
significant results.39,45 
 Associations between EOL discussion and chemotherapy use near EOL were mixed. For 
example, Mack and colleagues (n = 1,231) found patients who had EOL discussions were less 
likely to have chemotherapy in the last 14 days of life (OR 0.41, p < 0.001)23 and Hoerger and 
colleagues (n = 171) found palliative care visits that addressed treatment decisions were 
associated with lower odds of a patient receiving new chemotherapy within 60 days of death (OR 
0.57, 95% CI 0.35 to 0.90, p =0.02).38 However, Ahluwalia and colleagues (n = 665), who defined 
EOL discussion as any documented care planning discussion in the first month following cancer 
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diagnosis among veterans, did not find an association between discussion and chemotherapy 
near death (OR: 0.79, p = 0.35).39 With or without an EOL discussion, Garrido and colleagues 
found baseline chemotherapy (median 3.5 months before death) was significantly associated with 
higher costs of care in the last week of life.42 Studies of AD or POLST use did not assess late 
chemotherapy as an outcome.35,44 
Earlier EOL discussion associated with stronger outcomes. Finally, the six studies that 
explored associations between EOL communications and care-related outcomes in the context of 
time identified significant associations.1,23,37,39,47,49 Of the studies that exclusively looked at EOL 
discussions not AD or POLST documentation, earlier conversations (defined as occurring 30-31 
days or more before death, typically in inpatient settings) were found to be associated with lower 
likelihood of receiving any aggressive care in the last 30 days or life (ORs ranged 0.10 to 
0.34),1,23 lower likelihood of receiving acute care in the last 30 days of life (ORs ranged 0.03 to 
0.67),1,23,39 lower likelihood of ICU care in the last 30 days of life (ORs ranged 0.19 to 0.33),1,23 
and greater likelihood of enrollment in hospice care (OR 2.8, 95% CI 2.06 to 3.75, p< 0.001).23  
Some studies did not find significant associations between the timing of EOL discussions and 
hospice care or did not measure hospice enrollment overall but did measure time between 
hospice enrollment and death. Lopez-Acevedo and colleagues, for example, found early EOL 
discussions were associated with significantly more days of hospice care before death (median 
length of enrollment 53 days vs. 11 days, p < 0.001) and a lower likelihood of late enrollment in 
hospice within three days of death (OR 0.16, p = 0.02).1 Zakhour and colleagues, whose sample 
predominantly engaged in GOC discussions but also may have completed ADs or POLST, found 
patients who had late EOL discussions were eight times as likely to either enroll in hospice within 
three days of death or not enroll at all (OR 8.0, 95% CI 3.3-19.2, p < 0.0001) than those who had 
an early conversation.37 Earlier conversations were also associated with a much greater 
likelihood of patients dying outside the hospital (OR 8.9, p = 0.0001) compared to late 
conversations.1 
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Variation in conceptualization of EOL discussions. We found wide variation in how 
studies defined EOL discussions. Most studies based EOL discussions on documentation in the 
medical record or patient/surrogate reports of an EOL conversation with a healthcare provider; 
and others defined ACP in terms of documentation of medical orders such as DNR/DNI, POLST, 
AD, or living will. Some studies conceptualized EOL communication as a mix of terms. Eckert and 
colleagues, for example, defined ACP as documentation of an outpatient GOC conversation, AD 
or POLST, and/or DNR/DNI code status.34 Professional health providers led most discussions, 
though two studies featured professionally-trained lay healthcare workers, reflecting trends to 
train both lay workers and a growing body of primary palliative care providers.45,50 The wide 
variation in how clinicians and researchers define EOL discussions makes comparison difficult. 
Variation in healthcare utilization outcomes. We also found wide variation in EOL 
healthcare utilization outcomes measured. These measures serve as proxies for costs, but also 
represent variance in how clinicians conceptualize aggressive care and overuse of healthcare 
services near EOL. For example, Loggers and colleagues defined intensive EOL care as 
resuscitation and/or ventilation in the last week of life followed by death in the ICU or hospice,43 
whereas Ahluwalia and colleagues defined an intensive intervention as any of the following 
occurring in the last 30 days of life: an ICU admission, new hemodialysis, placement of a gastric 
tube, new mechanical ventilation, or death despite attempts at cardiopulmonary resuscitation 
(CPR).39 Furthermore, Mack and colleagues measured ICU care in the last 30 days or life, but 
also grouped measures into a category called “aggressive care” that included any ICU care or 
acute care in the last 30 days of life, or chemotherapy in the last 14 days of life.23 Similar 
variations in conceptualizing or grouping measures were common across studies, making clean 
comparisons difficult. These findings suggest a lack of standardization in what may represent 
unnecessary care near EOL. 
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Discussion 
 This systematic review evaluated the relationship between EOL discussions about care 
planning and EOL costs, healthcare utilization, and place of death in persons with advanced 
cancer. The 20 included studies provide evidence that an EOL discussion is associated with less 
costly and less aggressive or intensive forms of care near EOL, and greater use of hospice 
services; and that relationships are even stronger when conversations occur 30 days or more 
before death. Findings were similar for studies that assessed proxies for EOL discussion such as 
ADs, POLST, and DNR orders. The implications of these findings are significant. 
  First, it appears patient-provider EOL discussions influence patients’ decisions to receive 
less aggressive, less costly care at EOL, possibly due to a patient’s increased knowledge and 
understanding of their illness and care options. Because less aggressive, less costly EOL care is 
associated with numerous quality outcomes,1-4,55 EOL discussions about care preferences may 
help improve the EOL experience for patients and families.3 To improve the EOL experience, 
clinicians should routinely have these conversations with cancer patients—and in a timely matter, 
not just in the weeks or days before death. For patients with cancer who are hospitalized, it is 
critical that clinicians initiate these discussions early in the hospital stay. 
Although none of the studies assessed EOL costs or healthcare utilization by race, some 
studies did find evidence that racial minorities were less likely than Whites to have these 
important EOL discussions with their healthcare providers,23,40 a finding that is consistent with the 
literature.56-58  For example, Mack and colleagues found that compared to White patients, African 
American patients (OR 0.37, 95% CI 0.19 to 0.73) and Hispanic patients (OR 0.29, 95% CI 0.12 
to 0.73) were less likely to experience EOL discussions (p = 0.005).23 Clinicians should initiate 
EOL discussions with all their patients, especially racial and ethnic minorities who may be less 
likely to have these conversations.  
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 As part of EOL care planning, clinicians may also consider discussing patients’ financial 
wellbeing and the estimated costs of treatment options—not to make clinical decisions based on 
costs, but to acknowledge the financial burden cancer care has on patients and families and 
support informed decision-making. A majority of cancer patients report some desire to discuss 
treatment-related out-of-pocket costs with their care team, but less than 20% of patients actually 
discuss costs with their doctors.59 In the study by Apostol and colleagues, the need patients 
reported providers most poorly met in GOC conversations was the need for more economic and 
insurance information related to cancer,40 further supporting the idea that such conversations 
matter. The high cost of cancer care is associated with decreased quality of life and increased 
risk of mortality and morbidity,9-11 making it a clinical and ethical concern.  
End-of-life discussions also influence hospital and payer costs. One recent study found 
palliative care consultations for GOC/EOL were associated with a decrease in future acute care 
utilization, reducing future costs by more than $6,000 per patient.15 Although EOL discussions 
should never be used to deny necessary care, hospitals and payers may benefit from patients 
choosing less costly forms of care when consistent with patient goals. Finally, this review 
highlights the need for more research about EOL communication and costs, the timing of 
discussions, and racial/ethnic disparities across such measures. Standardization of outcome 
measurement and greater consistency in definition of outcomes is recommended.  
Limitations 
 This review has several limitations. First, only one study tested causal relationships 
through an RCT.50 This study was also the only study to assess associations among EOL 
discussions for GOC and costs;50 the other two cost studies compared AD utilization or did not 
adequately provide cost data.41,42 Third, studies did not account for the same utilization variables, 
consistently define the variables, or collect data on variables the same way. Studies that used 
self-report to measure EOL conversations could not account for recall bias, while studies using 
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medical records could not account for undocumented conversations. Fourth, variation in 
healthcare utilization variables limits study comparison. Finally, studies captured results in 
different cancer populations and healthcare systems that have varying levels of efficiency, rates 
of intensive care at EOL, training in EOL communications, and resources.39 These differences 
may limit generalizability of results. Despite these limitations, this review provides clinical insights 
that may help improve EOL care for persons with cancer and justify investment in EOL 
communication interventions. 
Ethical Considerations 
This review provides preliminary evidence that EOL discussions may reduce costs and 
utilization of aggressive EOL care. Reducing costs should not be a driving reason for engaging 
patients in EOL discussions.60 Instead, clinicians and payers should consider EOL discussions an 
intervention that uniquely increases patient autonomy, improves quality of care and quality of 
death, and saves resources at the same time.25 When communication is improved, better quality 
results and lower costs tend to follow, mutually benefitting patients and systems and further 
strengthening the case for EOL discussions. 
Conclusions 
End-of-life discussions are associated with lower EOL costs, less acute and aggressive 
care, less time spent hospitalized, greater use of hospice, and greater odds of dying outside the 
hospital—all outcomes associated with greater quality of life and quality of care. Separately, ADs 
and POLST documentation are similarly associated with reductions in intensive care at EOL. 
Earlier discussions about care goals give patients with advanced cancer more time to make 
informed decisions and result in higher quality EOL care that happens to be less costly. Clinicians 
should initiate EOL discussions with patients earlier to support patient-centered care and enable 
informed decision-making. More standardized research is needed to better understand 
relationships between these important discussions, healthcare utilization, and costs. 
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Illustrations and Tables 
 
Figure 2.1 PRISMA flow diagram showing systematic review screening and inclusion process, 
adapted from Moher and colleagues 1 
 
 
1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41. 
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Table 2.1 Systematic Review search strategy in PubMed, Embase, and CINAHL 
 
Cancer terms "Neoplasms"[mesh] OR cancer OR oncolog* 
EOL terms "end of life" OR end-of-life OR "terminal care"[mesh] OR end-stage OR 
advanced OR "stage III" OR "stage iv" OR terminal* 
Communication 
terms 
communicat* OR discuss* OR conversation* OR "advanc* care plan*" 
OR "advanc* directive*" OR "goals of care" OR polst OR "physician 
order for life sustaining treatment” 
Financial terms financ* OR "loss of income" OR "productivity loss" OR "economic 
burden*" OR "aggressive treatment" OR "aggressive care" OR 
"intensive care" OR ICU* OR "length of stay" OR "emergency room*" 
OR "emergency department" OR readmission* OR re-admission* OR 
readmi* OR hospice* OR cost* OR debt* OR bankrupt* OR "out of 
pocket" OR out-of-pocket OR "Cost of Illness"[Mesh] OR "personal 
cost*" OR "financial toxicity" OR expense* OR "financial burden” 
Excluded terms pediatric* OR paediatric* OR child* OR infan* OR neonat* OR newborn* 
OR adolescen* OR Britain OR Japan OR Uganda OR Korea OR Italy 
OR Ireland OR Australia[MeSH Terms] 
Publication 
dates 
January 2012- January 9, 2019 
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D
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m
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on
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O
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T,
 2
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m
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er
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m
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C
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G
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m
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et
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C
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m
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%
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%
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%
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h 
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C
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n 
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in
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n 
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m
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P 
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s 
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. 
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- E
R
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w
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 1
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 3
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C
U
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is
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w
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in
 1
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w
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30
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Pa
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w
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 s
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m
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C
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w
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w
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in
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4 
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, p
 =
 0
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C
P 
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w
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R
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w
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th
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O
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%
 lu
ng
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ce
r, 
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%
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 w
ou
ld
 
lik
e 
to
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U
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O
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O
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sc
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s 
ra
tio
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O
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U
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O
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m
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Q
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n 
m
ea
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pa
re
d 
to
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ie
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tie
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O
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w
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30
%
 b
on
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he
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n 
Pa
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O
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er
sa
tio
ns
 th
em
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m
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w
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iv
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m
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ra
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tm
en
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CHAPTER THREE: PALLIATIVE CARE CONSULTATION FOR GOALS-OF-CARE 
AND FUTURE HEALTHCARE UTILIZATION AND COSTS AMONG AFRICAN 
AMERICAN AND WHITE PATIENTS: A PROPENSITY-MATCHED STUDY 
Abstract 
Background: End-of-life (EOL) medical costs are higher for racial/ethnic minorities than Whites 
in the United States. Palliative care consultation to discuss goals-of-care (hereafter “PCC”) is 
associated with lower use of intensive care and cost-savings. Little is known about how PCC-
associated cost and utilization outcomes differ among African Americans and Whites. 
Objective: To compare future acute care costs and healthcare utilization (30-day readmissions, 
future hospital days, future ICU admission and number of ICU days, and discharge to hospice) 
between African Americans who had inpatient PCC (n = 383) and a propensity-matched cohort of 
African Americans who did not (n = 10,777) and between Whites who had PCC (n = 814) and a 
propensity-matched cohort of Whites who did not (n = 23,180) in an academic medical center. 
Methods: In this secondary analysis of a retrospective cohort study, stratified propensity score 
modeling was applied using sociodemographic, clinical, and financial variables to account for 
potential inherent differences between the race-based groups with and without PCC. 
Results: There was no statistically significant difference between African Americans with or 
without PCC in accumulated mean future acute care costs ($11,651 vs. $15,050, P = 0.09), 30-
day readmissions (P = 0.58), future hospital days (P = 0.34) future ICU admission (P = 0.25) or 
number ICU days (P = 0.30). However, there was a significant difference between Whites with 
PCC compared to Whites without PCC in in accumulated mean future acute care costs ($8,095 
vs. $16,799, P < 0.001), 30-day readmissions (10.2% vs. 16.7%, P < 0.0001), future days spent 
hospitalized (3.7 vs. 6.3 days, P < 0.0001). PCC resulted in significantly greater discharge to 
hospice from index hospitalization for both African Americans and Whites (African Americans with 
PCC and without PCC, respectively, 36.5% vs. 2.4%, P < 0.0001; Whites with PCC and without 
PCC, respectively, 42.7% vs. 3.0%, P < 0.0001).  
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Conclusions: Our findings suggest PCC appears to decrease future acute care utilization and 
costs in White patients and, directionally but not significantly, in African Americans. Research is 
needed to explain why acute care utilization and cost disparities persist among African Americans 
despite PCC. These consultations are effective at dramatically increasing hospice use among 
African American and White patients. 
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Introduction 
Despite growing evidence that patient-provider discussions about goals-of-care (GOC) 
and end-of-life issues (EOL) are associated with patients receiving EOL care concordant with 
preferences1,2 and less aggressive treatment3-13 perceived to be higher quality,12,14-16 African 
Americans and other racial/ethnic minorities in the United States are less likely than Whites to 
have such conversations with their healthcare providers.17-22 This disparity suggests an unmet 
need that may result in lower quality care.17,23 Because race does not determine EOL 
preferences24,25 and communication-based interventions can affect such preferences,24,26 it is 
important to understand relationships between GOC discussions and the EOL care African 
Americans and other racial minorities receive.27 
Communication disparities and differences in the effectiveness of EOL discussions22 may 
help explain why minority patients are more likely than White patients to prefer and receive 
intensive EOL care17,23,28-34 and less likely to receive hospice care.35,36 These differences in 
healthcare utilization contribute to acute care spending disparities near EOL. One large study of 
Medicare data found that in the last six months of life, medical costs were 32% higher for African 
Americans and 57% higher for Hispanics compared to Whites; and that about 40% of the higher 
costs for racial/ethnic minorities was due to greater use of intensive procedures (e.g., mechanical 
ventilation, gastrostomies) and intensive care unit (ICU) hospitalization.28 African Americans and 
Hispanics are also more likely to die in hospitals compared to Whites,28 adding to differences in 
costs. Across races/ethnicities, expenditure is dramatically higher in the last month of life, with 
African Americans and Hispanics receiving the most aggressive and costly care.28 These 
disparities in EOL costs persist across studies, even after controlling for individual and 
geographic factors.37  Unfortunately, high medical costs at EOL are associated with worse quality 
death, underscoring the ethical need to understand EOL cost disparities among racial/ethnic 
groups and interventions, such as palliative care consultation, that mitigate those disparities.12,38  
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Palliative care consultations may involve discussion of GOC, pain and symptom 
management, psychosocial or spiritual distress, transition planning, or EOL issues. Inpatient 
palliative care consultations that specifically address GOC (hereafter called “PCC”), however, 
have been found to be associated with reductions in future acute care utilization, hospital 
readmissions, hospital days, and ICU use; and an average savings of over $6,000 in acute care 
costs following discharge from a hospitalization with PCC.6 Some studies suggest cost reductions 
associated with GOC discussions, such as those occurring in PCC, are driven by lower utilization 
of inpatient care.12,39,40 The benefit of PCC for patients and health systems appears to be mutual: 
patients who have these conversations seem to experience a higher quality dying experience 
more consistent with their preferences and health systems incur lower costs as a result.12 In 
addition, early evidence of urban academic medical centers suggests race/ethnicity is not a factor 
in which patients receive PCC,6,41-43 making it an intervention that may help overcome 
racial/ethnic disparities in EOL communication and care.  
However, it is unknown how PCC is associated with acute care utilization and costs 
across racial groups, particularly among African Americans. The purpose of this secondary 
analysis is to compare future acute care costs and healthcare utilization (30-day readmissions, 
future hospital days, future ICU admission and number of ICU days, and discharge to hospice) 
between African Americans with serious illness who had PCC and a propensity-matched cohort 
of African Americans who did not, and between Whites with serious illness who had PCC and a 
propensity-matched cohort of Whites who did not. In addition, patients self-reporting as Hispanic, 
Asian, and “Other” racial/ethnic minorities will be described using demographic, cost, and 
utilization variables. The presence of a do-not-resuscitate (DNR) order during index admission 
and, among PCC patients, whether GOC changed during index admission will also be described. 
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Methods 
Study Design 
This secondary analysis included pre-existing clinical, administrative, and cost data from 
a retrospective cohort study that found PCC was associated with lower costs and lower use of 
acute care, but did not explore outcomes by race.6  Supplementary Medicaid data was pulled 
from electronic medical records. Our sample included 35,154 self-identified African American and 
White patients 18 years or older admitted to a 776-bed urban, academic medical center in the 
Northeast region between July 1, 2014 and October 31, 2016 who were admitted for conditions 
other than childbirth or rehabilitation, were not hospitalized at the end of the study period, and did 
not die during index hospitalization (defined as the hospitalization during which the first PCC 
occurred). The hospital’s palliative care registry, which includes demographic and clinical 
information such as the reason for consultation, was used to identify all patients who received a 
consultation with palliative care during the study period. Only consultations involving discussion of 
GOC were included (i.e., consultations to discuss pain management, but not GOC, were 
excluded). Our sample included 11,158 African Americans (PCC = 383; No PCC = 10,777) and 
23,994 Whites (PCC = 814; No PCC = 23,180) (Table 3.1).  
Future acute care utilization and accumulated direct costs (Appendix A) were tracked 
forward after discharge from the index hospital admission through the end of the study period 
using the medical center’s cost accounting system (McKesson Health Solutions, King of Prussia, 
PA).6 (Utilization and costs incurred during the index admission were not included in analysis, but 
are described in Table 3.1.) Direct costs represent the best estimate of the actual cost of 
providing hospital services including nursing labor, other allied health professional labor, 
pharmaceuticals, supplies, procedures, and testing (Appendix A).6 
Setting 
According to research by the medical center, the center serves a diverse area composed 
of 46% African Americans, 36% Whites, 9% Asians, and 6% Hispanics44 and receives transfer 
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patients and referrals from surrounding suburban areas. Over half (53%) of families in the 
medical center’s main service area live in poverty and one in four adults 60+ are in fair or poor 
health,44  contributing to the population’s diversity and need for quality care. The medical center’s 
palliative care team is well-established and predominantly works as a consultation service.6 
Physicians, advance practice nurses, registered nurses, social workers, a pharmacist, and a 
chaplain make up the team. ICU teams request one-third of all consultations with palliative care.6  
Procedures 
The institutional review board of the University of Pennsylvania approved this secondary 
analysis study. The study followed University of Pennsylvania procedures for ensuring patient 
data privacy and security. To ensure Health Insurance Portability and Accountability Act (HIPAA) 
compliancy and participant privacy, all HIPAA-identifiers were removed prior to data transfer. 
Penn Medicine transferred de-identified data through Secure Share, an internet-based application 
for secure file exchange. Data was saved to a secure, encrypted folder on the University of 
Pennsylvania School of Nursing’s network drive that exists behind firewall protection. Accessing 
the folder and the network drive requires two-step authentication. The network drive that 
contained the data is routinely monitored for system and security breaches. Only study 
investigators and university statisticians had access to the data.  
Power Analysis 
Based on the parent study’s finding of $8,831 in future acute care costs among patients 
with PCC and $15,654 for patients without PCC, and variance of 10% (standard deviation 
unreported),6 a sample of 771 Non-White patients who received PCC and a cohort of 15,780 
Non-White patients who did not receive PCC achieves 91% power to detect a clinically 
meaningful difference of at least $2,000 in mean future acute care costs with a significance level 
(alpha) of 0.01 using a two-sided two-sample unequal variance t-test.30,31,33 (The majority of Non-
White patients in the dataset were African American.6) A $2,000 difference is a conservative 
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estimate given the parent study’s finding of $6,000 cost-savings among the entire study 
population6 and suggests adequate power in this study.  
Measures 
Independent variable. The primary independent variable is PCC as recorded in the 
palliative care registry according to patient self-identified racial group (African American, White). 
All hospital admissions during the study period were placed into one of four groups: (1) African 
Americans who had PCC, (2) African Americans who did not have PCC, (3) Whites who had 
PCC, and (4) Whites who did not have PCC (Appendix A). Although propensity score-matched 
analysis of other racial/ethnic groups is desirable, sample sizes for other racial and ethnic groups 
(Hispanics, Asians, American Indian/Alaskan Natives, Native Hawaiian/Pacific Islanders) were 
too small for independent group analysis. These patient populations are described using available 
clinical and cost variables (Tables 7-10, Appendix A).  
Outcomes 
Future Acute Care Costs. The primary outcome is future acute care costs, defined as 
accumulated mean acute care costs from all hospitalizations after the index hospitalization during 
the study period (Appendix A). We measured “future acute care costs” in two ways: (1) if a 
patient had any direct future acute care costs following discharge from index admission (yes, no) 
and (2) total direct future acute care costs a patient had during the study period following 
discharge from index admission, measured in U.S. dollars. Direct costs include hospital services 
such as physician and nursing labor, allied health professional labor, pharmaceuticals, supplies, 
procedures, testing, and emergency department (ED) visits that resulted in hospitalization. Direct 
costs provide the best estimate of actual costs, as they exclude indirect or fixed costs (i.e., 
overhead costs such as the cost of utilities) that cannot be reduced by avoiding future 
hospitalizations 6. The medical center’s cost accounting system, McKesson Health Solutions 
(King of Prussia, PA), provided acute care costs data based on charges coded during each 
hospital encounter throughout the study period. Healthcare costs outside the health system, such 
 
 
70 
as emergency room visits at local hospitals unaffiliated with the medical center, were not 
available and therefore not included, and have been identified as a limitation. 
Future Healthcare Utilization. Secondary outcomes include (1) the number of future 
hospital days (in the health system) following discharge from the index hospital admission, (2) the 
number of future ICU days (in the health system) following discharge from the index hospital 
admission, (3) any ICU care following discharge from the index hospital admission (yes, no), (4) 
30-day readmissions (in the health system) following discharge from index admission, and (5) 
patient discharge to hospice from index admission (yes, no) (Appendix A). 
Covariates 
Covariates include demographic variables such as age, gender, and Medicaid status 
(yes, no); acute care utilization 30 days before index hospitalization (yes, no); acute care costs 
accumulated during the index admission to represent acute care utilization (defined as the impact 
of $1,000; for every increase of $1000 in direct costs, the estimate shows the expected increase 
in getting a palliative care consult); and the following clinical variables (1) primary diagnosis at the 
time of index hospitalization discharge [based on diagnosis-related group (DRG)], (2) All Patient 
Refined (APR)-DRG Severity of Illness at the time of index admission discharge, (3) APR-DRG 
Risk of Mortality at the time of index admission discharge, (4) if the patient had any ICU care 
during the index admission (yes, no), (5) if the patient had ICU care greater than six days during 
the index admission (yes, no), and (6) whether the patient had Oncology services during the 
index admission (Appendix A).6 
APR-DRG Severity of Illness and Risk of Mortality. APR-DRG Severity of Illness, which 
indicates the extent of physiologic decomposition or organ system loss of function in a patient, 
and APR-DRG Risk of Mortality, which indicates the likelihood a patient will die in the hospital, 
feature four subcategories (minor, moderate, major, extreme) that are assigned to a patient at 
discharge by an algorithm in the hospital’s medical record software based on the diagnoses and 
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procedures coded for billing during the hospitalization.6,45 Developed by 3M (St. Paul, MN) to 
enable hospitals to analyze patient risk and possible resource use, APR-DRG Severity of Illness 
and Risk of Mortality scores take into account a patient’s comorbidities and the interaction of 
those illnesses, disease staging, and the kind of procedures and resources required by a patient 
during hospitalization.46 High Severity of Illness and Risk of Mortality are characterized by 
multiple serious diseases and the interaction among those diseases. Severity of Illness appears 
to be associated with the risks of morbidity and mortality,47 making it a proxy for considering 
comorbidity severity. Our study is unable to account for the number of comorbidities each patient 
has due to limitations in the dataset but uses Severity of Illness and Risk of Mortality to 
meaningfully express how sick a patient is at the time of index hospitalization.  
Secondary Aims 
Patients who self-identified as Asian, Hispanic, and “Other” race/ethnicity were not 
included in this propensity score-matched study. However, the parent dataset6 included an 
additional 4,733 patients 18 years and older who self-reported to be a race/ethnicity other than 
African American or White who met our study criteria. These patients were also discharged from 
an inpatient hospitalization at the academic medical center and excluded patients who had been 
admitted for childbirth or rehabilitation, patients who died during index admission, and patients 
still hospitalized at the end of the study period. 
For the secondary descriptive aim, which did not include propensity score matching to 
account for differences in patients with and without PCC, the sample included 961 Asians (PCC = 
48; No PCC = 913); 851 Hispanics (PCC = 22; No PCC = 829); and 1,134 patients with “Other” 
race/ethnicity (PCC = 39; No PCC = 1,095). Healthcare utilization and costs of these patients are 
described in Tables 3.7-3.10. In addition, the presence of a DNR order during index admission 
(Table 3.6) and whether a patient changed GOC during PCC are described for African. 
Americans, Whites, Asians, Hispanics, and other racial/ethnic minority patients (Table 3.1, 
Tables 3.7-3.10). 
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Statistical Methods 
Descriptive statistics were generated to characterize all variables and describe the 
sample (Table 3.1). Continuous variables were described using means and standard deviations 
following analysis with a Student’s t test. Categorical variables were described as frequencies 
and percentages using a Chi-squared (χ2) test. For the PCC groups, whether or not the patient 
changed GOC preferences is also included. 
 A systematic process to balance the four PCC-race groups (African Americans with and 
without PCC, Whites with and without PCC) was followed (Tables 3.2 and 3.3). We created two 
stratified propensity score matching models: one in the African American sample and then, 
separately, one in the White sample to account for possible inherent differences and nonrandom 
assignment of variables in the PCC and Non-PCC groups within each racial group. Before 
propensity scoring, patients in the PCC and Non-PCC groups for each race had different baseline 
characteristics (Table 3.1). For this reason, we employed a two-step matching process to make 
the PCC and Non-PCC groups similar for each race. First, we used logistic regression analysis 
with relevant variables available in the dataset to identify factors associated with the likelihood of 
an individual receiving PCC (Table 3.2). These variables included demographic data such as 
gender, age at time of index admission, and Medicaid status; and clinical and utilization data 
including primary diagnosis, APR-DRG risk of morality and severity of illness at the time of index 
admission discharge, ICU care during index admission (yes, no), ICU care greater than six days 
during index admission to indicate high acuity during the hospitalization, index admission acute 
care costs to represent acute care utilization; and prior inpatient hospitalizations in the health 
system during the 30 days before index admission. 
The results from the final logistic model for African Americans and the results of the final 
logistic model for Whites are presented in Table 3.2. In both models, both the Akaike Information 
Criterion (AIC) and the Schwarz Criterion (SC) values became substantially lower when the 
covariates were included, showing much of the variation was explained by the predictors. As a 
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result, the model of African American PCC and Non-PCC patients had a C statistic of 0.907, 
indicating adequate model fit. The model of White PCC and Non-PCC patients had a C statistic of 
0.901, also indicating adequate model fit. 
Individual-level propensity scores were then created for each patient in the sample using 
output from the logistic regression models, by racial group. These individual propensity scores 
were then ranked and stratified into propensity tiers, from highest to lowest, to identify which 
patients were most likely to have received PCC (Table 3.3). Patients in the highest tiers were 
most likely to have received PCC. For each racial group’s model, the patients in the PCC and 
Non-PCC groups were similar in terms of their propensity scores (Table 3.3), which enabled 
direct comparison of PCC patients to Non-PCC patients within tiers, within each racial group 
(Tables 3.4 and 3.5). To understand outcomes among patients with the highest likelihood of 
receiving PCC per racial group, subsequent analysis focused on the two highest tiers of 
propensity scores for each model. Lower propensity tiers were excluded because very few 
patients with a low propensity score actually received PCC. Significance tests for continuous 
variables were analyzed using a pooled t test and percentage variables were analyzed using a 
Cochran–Mantel–Haenszel test. Statistical significance was taken at the 0.05 level.  
Missing Data 
 Although clinicians try to obtain and document complete data on every patient, missing 
clinical and administrative data is inevitable due to human error, oversight, or time constraints.48 
The parent study handled missing data by examining the underlying mechanism for missing 
data—missing completely at random (MCAR), nonignorable or not missing at random (NMAR)— 
prior to adjusting to minimize bias from missing data.48-50 Most missing data was found to be 
MCAR (e.g., clinicians may have found data collection burdensome). For this reason, complete-
case only analyses for data missing completely at random was used to analyze missingness. 
Although the number of patients with missing data was small (<5%) and missing data was 
considered MCAR, the parent study opted to exclude 0.4% of patients due to missing data. 
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Primary hypotheses were then tested on the remaining dataset. There was no missing data for 
our study, so additional analyses were not necessary.  
Results 
The sample for this study included 35,154 patients who were discharged from an 
inpatient hospitalization at an academic medical center in the Northeast region (Table 3.1). The 
sample included 1,197 patients who received PCC prior to discharge and 33,957 patients who did 
not. Specifically, the sample was composed of 11,160 African American patients (PCC = 383, 
Non-PCC = 10,777) and 23,994 White patients (PCC = 814, Non-PCC = 23,180).  
At baseline, before propensity score matching, African Americans in the PCC group were 
significantly different from African Americans in the Non-PCC group (Table 3.1). Compared to 
African Americans who did not receive PCC, African Americans who received PCC were more 
likely to be older; less likely to have Medicaid; more likely to have cancer, a cardiovascular 
disorder or heart failure, a respiratory disorder, an infectious disease or sepsis and less likely to 
have an endocrine disorder, GI disorder, gynecologic or urologic disorder, neurologic disorder, or 
“other” condition; more likely to have major or severe severity of illness; more likely to have major 
or severe risk of mortality; more likely to have been hospitalized in the 30 days prior to index 
admission; more likely to have had ICU care during the index admission; more likely to have had 
ICU care for greater than six days during the index admission; more likely to have been seen by 
Oncology providers during the index admission. These differences are reflected in PCC patients’ 
average utilization and costs during index admission. Compared to African Americans without 
PCC at baseline, African Americans with PCC had longer length of stay, more days in the ICU, 
and more than twice the average direct costs accrued during index admission, suggesting sicker 
African American patients received PCC. 
At baseline, before propensity score matching, White patients in the PCC group were 
also significantly different from White patients in the Non-PCC group (Table 3.1). Compared to 
Whites who didn’t receive PCC, Whites who received PCC were older; more likely to have 
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cancer, an infectious disease or sepsis, or a respiratory disorder and less likely to have a 
cardiovascular disorder or heart failure, endocrine disorder, GI disorder, gynecologic or urologic 
disorder, neurologic disorder, or “other” condition; more likely to have major or severe severity of 
illness; more likely to have major or severe risk of mortality; more likely to have been hospitalized 
in the 30 days prior to index hospitalization; more likely to have received ICU care during index 
admission; more likely to have received ICU care for more than six days during index admission; 
more likely to have been seen by Oncology providers during index admission; and more likely to 
have a DNR documented during the index admission. Like African Americans, these differences 
are reflected in PCC patients’ average utilization and costs during index admission. Compared to 
Whites without PCC at baseline, Whites with PCC had longer length of stay, more days in the 
ICU, and twice the average direct costs accrued during index admission, also suggesting sicker 
White patients received PCC. 
After the African American PCC and Non-PCC groups were propensity score matched on 
available variables (Table 3.2), the group of African Americans who received PCC and the group 
of African Americans who did not became similar (Table 3.3), such that the only difference between 
the groups was whether or not a patient had PCC. The groups of Whites who had PCC and Whites 
who did not have PCC also became similar after propensity score matching (Table 3.3). By 
matching variables within racial groups such that PCC is the only difference between groups within 
races, we were able to identify differences in outcomes associated with PCC. 
Cost Outcomes 
Any future acute care cost. Compared to African American patients who received PCC, 
African American patients who did not receive PCC were significantly more likely to incur “any 
future acute care cost” across the two highest propensity tiers when blended (31.9% vs. 37.7%, P 
= 0.047), but not when tiers were assessed separately (highest tier, 33.7% vs. 38%, P = 0.26; 
second highest tier, 29.5% vs. 37.3%, P = 0.08) (Table 3.4). White patients who received PCC 
were also significantly less likely than White patients who did not receive PCC to incur “any future 
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acute care cost” across the two highest propensity tiers when blended (25.9% vs. 35.5%, P < 
0.0001) and when top tiers were assessed separately (highest propensity tier, 26.9% vs. 33.9%, P 
= 0.008; second highest propensity tier, 24.5% vs. 37.2%, P < 0.0001) (Table 3.5).  
Total future acute care costs. Although average accumulated future acute care costs were 
lower across propensity tiers among African Americans with PCC compared to those without PCC 
(highest tier, $11,452 vs. $15,867, P = 0.055; second highest tier, $11,925 vs. $14,256, P = 0.53; 
blended top two tiers, $11,651 vs. $15,050, P = 0.09), the differences were not statistically 
significant (Table 3.4). Data support a trend toward an average difference in future acute care costs 
of $4,415 between PCC and Non-PCC African American groups in the highest propensity tier, but 
the difference was not statistically significant (P = 0.055). However, average future acute care costs 
were significantly lower among Whites who had PCC across tiers (highest tier, $8,302 vs. $14,995, 
P < 0.0001; second highest tier, $7,813 vs.  $18,558, P < 0.001) and when the top two tiers were 
blended ($8,095 vs. $16,799, P < 0.001) (Table 3.5). In effect, PCC among Whites is associated 
with an average difference in future acute care costs of $6,693 (highest tier) to $10,745 (second 
highest tier) per person ($8,704 difference in blended top tiers). A large effect-size difference is 
represented among White patients with PCC. 
Healthcare Utilization Outcomes  
Increase in hospice utilization among African Americans and Whites. African American 
patients with PCC were more likely to be discharged to hospice from index admission than African 
Americans without PCC (highest tier, 30.3% vs. 2.6%, P <0.0001; second highest tier, 45% vs. 
2.3%, P < 0.0001; blended top tiers, 36.5% vs. 2.4%, P < 0.0001) (Table 3.4). White patients with 
PCC were also more likely than White patients without PCC to be discharged to hospice from index 
admission (highest tier, 41.1% vs. 3.3%, P <0.0001; second highest tier, 44.8% vs. 2.8%, P < 
0.0001; blended top tiers, 42.7% vs. 3.0%, P < 0.0001) (Table 3.5). 
30-day readmissions. Significant differences among African Americans with and without 
PCC were not evident in 30-day readmission rates (highest tier, 15.7% vs. 16.3%, P = 0.84; second 
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highest tier, 17.8% vs. 14.6%, P = 0.31; blended top tiers, 16.6% vs. 15.4%, P = 0.58), but were 
evident among Whites with PCC compared to Whites without PCC (highest tier, 11.4% vs. 15.8%, 
P = 0.03; second highest tier, 8.6% vs. 17.6%, P = 0.0002; blended top two tiers, 10.2% vs. 16.7%, 
P < 0.0001). 
Future days in hospital post-discharge. Significant differences in the number of future 
hospitalized days were not found among African Americans with and without PCC (highest tier, 5.8 
vs. 6.7 days, P = 0.18; second highest tier, 5.5 vs. 6.0 days, P = 0.74; blended top two tiers, 5.5 
vs. 6.4 days, P = 0.34), but were found among Whites with PCC compared to Whites without PCC 
(highest tier, 3.6 vs. 5.7 days, P = 0.04; second highest tier, 3.9 vs. 7.0 days, P = 0.0006; blended 
top two tiers, 3.7 vs. 6.3 days, P < 0.0001). 
Future admission to ICU. African Americans with PCC were no less likely than African 
Americans without PCC to be admitted to the ICU following index hospital discharge (highest tier, 
17.4% vs. 15.8%, P = 0.58; second highest tier, 15.5% vs. 12.6%, P = 0.34; blended top two tiers, 
16.6% vs. 14.2%, P = 0.25). Results were similar for Whites, among whom there were no significant 
differences in future ICU admission by PCC or Non-PCC group (highest tier, 12% vs. 13.9%, P = 
0.33; second highest tier, 13.2% vs. 14.9%, P = 0.46; blended top two tiers, 12.5% vs. 14.4%, P = 
0.20). 
Future days in ICU post-discharge. Significant differences in the number of future ICU days 
were also not found among African Americans with PCC compared to those without (highest tier, 
1.3 vs. 1.2 days, P = 0.81; second highest tier, 1.3 vs. 0.80 days, P = 0.28; blended top two tiers, 
1.3 vs. 0.99 days, P = 0.3). Among Whites with and without PCC, significant differences in the 
number of future ICU days were only evident in the highest propensity group (0.6 vs. 0.9 days, P = 
0.042; second highest tier, 1.0 vs. 1.6, P = 0.85; blended top two tiers, 0.8 vs. 1.0 days, P = 0.15). 
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Results of Secondary Aims  
 Presence of a DNR order during index admission. Table 3.6 describes differences in 
DNR documentation among the propensity-matched cohorts of African Americans and Whites 
with and without PCC. Although DNR documentation could not be assessed as an outcome 
because the timing of DNR documentation during index admission may have occurred before, 
during, or after PCC, associations with increased DNR documentation among PCC groups was 
also significant. Across tiers, African Americans with PCC were almost 9 times more likely to 
have a DNR than African Americans without PCC (blended top two tiers, 46% vs. 5%, P < 
0.0001). Similarly, Whites with PCC were 8.5 times more likely to have a DNR than Whites 
without PCC across tiers (blended top two tiers, 54% vs. 6%, P < 0.0001) (Table 3.6). 
Description of Asian patients with and without PCC. Table 3.7 describes Asian patients 
who had PCC (n = 48) and Asian patients who did not have PCC (n = 961) prior to discharge 
from index admission. Propensity score matching was not used on these groups to make them 
similar, so data is best understood as descriptive. However, some differences among groups was 
still apparent. For example, Asians with PCC had significantly greater mean number of hospital 
days, ICU days, and direct acute care costs incurred during index hospital admission than Asians 
without PCC (P < 0.0001). Almost six out of ten Asian PCC patients (58%) changed their GOC, 
likely contributing to the significantly higher hospice use at time of index discharge among Asian 
PCC patients (33.3% vs. 0.8%, P < 0.0001) and DNR documentation (35.4% vs. 2.4%, P < 
0.0001) compared to Asians without PCC. 
 Description of Hispanic patients with and without PCC. Propensity-score matching was 
also not applied to Hispanic patients in our sample. Table 3.8 describes Hispanic patients who 
had PCC (n = 22) and Hispanic patients who did not have PCC (n = 829) prior to discharge from 
index admission. Hispanics with PCC also had greater mean number of hospital days and ICU 
days (P < 0.0001), and direct acute care costs (P = 0.0005) incurred during index hospital 
admission than Hispanics without PCC. Similar to Asians, about six out of ten Hispanic PCC 
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patients (59.1%) changed their goals-of-care during PCC.  Hispanic PCC patients were also more 
likely to be discharged to hospice (31.8% vs. 0.4%, P <0.0001) and have a DNR documented 
during index admission (31.8% vs. 0.97%, P < 0.0001) compared to Hispanics without PCC.  
 Description of Other racial/ethnic minority patients. Table 3.9 describes patients with 
“Other” race/ethnicity (self-reported as “Other” race/ethnicity, American Indian or Alaska Native, 
or Native Hawaiian or Pacific Islander) who had PCC (n = 39) and did not have PCC (n = 1,095). 
These patients were also not matched using propensity scoring. Like all other patients in the 
sample, other racial/ethnic minority PCC patients had index admissions with higher mean number 
of days hospitalized (P <0.0001), higher mean number of days spent in the ICU (P < 0.0001), and 
higher mean direct acute care costs (P = 0.0002), indicating the greater acuity among PCC 
patients. Almost seven out of ten other racial/ethnic minority PCC patients changed their goals-of-
care during PCC. These PCC patients were also more likely to be discharged to hospice from 
index admission compared to Non-PCC patients (28.2% vs. 1.6%, P < 0.0001) and have a DNR 
(46.2% vs. 3.5%, P < 0.0001).  
 Descriptive comparison of PCC patients across racial/ethnic groups. Table 3.10 explores 
differences among PCC patients across racial/ethnic groups. Again, these racial groups were not 
matched on available variables. Patients with “unknown” race/ethnicity include those who did not 
self-report their race/ethnicity. While there was no difference in mean index admission costs (P = 
0.17), there was a statistically significant difference in median acute care costs accrued during 
the index admission (P = 0.04), with African American and Hispanic PCC patients spending the 
most, or most heavily using acute care services, consistent with other literature.28 Asian PCC 
patients accumulated the lowest median costs during index admission (median $14,739; IQR 
$24,510), but one of the highest mean costs ($46,739, SD $81,216), suggesting very high 
utilization among some Asian patients. Future acute care costs appear to differ by race, with any 
future cost (P = 0.004), mean future acute care costs (P = 0.047), and median future acute care 
costs (P = 0.02) all showing statistically significant differences. Thirty-day readmission rates also 
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significantly varied by race (mean 13.3% yes, P = 0.006), with African American and Hispanic 
PCC patients demonstrating the highest readmission rates (18.3%, 18.2% respectively) and 
White and Unknown race/ethnicity PCC groups demonstrating the lowest rates (11.6%, 4.8% 
respectively). Significant differences were also observed in the number of future hospital days 
(sample mean 4.5 days, P = 0.005; sample median 0.0 days, P = 0.01) across racial/ethnic 
groups, with African Americans (mean 6.6 days) and “Other” race/ethnicity (mean 6.9 days) PCC 
patients spending the most time hospitalized after discharge from index admission. Asian (mean 
3.1 days), White (3.9 days), and Unknown race/ethnicity (2.0 days) PCC patients spent the 
fewest days hospitalized following discharge (P = 0.005). 
 Although DNR documentation significantly varied by race/ethnicity (sample mean 49%, P 
= 0.03), with White (51.2%) and Unknown race/ethnicity (56%) PCC patients documenting 
resuscitation wishes most prevalently, and Hispanic (32%) and Asian (35%) PCC patients 
documenting such preferences least commonly, the most interesting finding is that the proportion 
of PCC patient who were discharged to hospice did not significantly differ across racial/ethnic 
groups (P = 0.16). Racial/ethnic disparities in discharge to hospice did not differ by racial group 
among patients who received PCC. The majority of PCC patients (65%) changed their GOC 
during PCC, which might explain high hospice use across racial groups. Whether a patient 
changed GOC during PCC also did not significantly differ by PCC racial group (P = 0.14). 
Discussion 
 This propensity-matched study found PCC is associated with statistically significant 
differences in 30-day readmissions, number of future days spent hospitalized, and accumulated 
mean future acute care costs (resulting in an average reduction of $8,704 per patient) in White 
patients, but no statistically significant differences in accumulated costs or acute care utilization in 
African Americans with PCC. It is unclear why these outcomes declined for White patients with 
PCC, but not African Americans with PCC. The higher proportion of White patients discharged to 
hospice from index admission (43% vs. 37%) may help explain some of these differences, as 
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hospice-eligible African American PCC patients not enrolled in hospice may have had greater or 
more frequent acute care utilization near EOL.51,52 One recent study found that the effect of 
inpatient PCC on 30-day readmissions in oncology was largely driven by hospice enrollment, 
suggesting hospice may help explain some of our findings.53  However, more research is needed 
to better understand why, when all available variables were held constant, PCC was associated 
with different cost and utilization outcomes among African American and White patients.  
Differences in outcomes between African American and White PCC groups may be 
explained by variables not measured in our study. Socioeconomic variables such as income and 
education, which have been found to help explain differences in ACP in African Americans,54 were 
not available in the dataset and may have contributed. Compared to Whites, African Americans 
endure significant systematic disadvantages resulting in disproportionate and poor economic 
resources to higher unemployment and lower incomes, which impact health, health literacy, and 
access to quality care.54,55 Patients with lower levels of education have been found to have lower 
levels of health literacy,54,56 which can influence how a patient understands, recalls, and applies 
information exchanged during PCC or other healthcare encounters.56,57 Patients with lower health 
literacy have an increased risk of hospital admission,58,59 use an inefficient mix of healthcare 
services,60 and have higher healthcare costs,60 all associations that may help explain why PCC 
among African Americans was not associated with acute care utilization and cost reductions. 
Specifically, socioeconomic disadvantages may have contributed to avoidable use of the 
emergency department (ED). According to the literature, low socioeconomic status is 
independently associated with increased use of the ED, regardless of the visit or medical condition 
urgency.61 Patients described as “working poor”62 who do not qualify for Medicaid, patients without 
access to timely care in the community,63 and patients with low health literacy who do not know 
how to navigate health resources64 may visit the ED for possibly preventable care and subsequently 
be hospitalized.64 Our study included the cost of ED visits that resulted in hospitalization, but 
excluded ED visits that did not involve inpatient care. It is therefore possible that patients who 
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visited the ED following discharge from an admission with PCC and were hospitalized for care that 
may have otherwise been treated in an outpatient setting also contributed to differences in future 
acute care cost totals among race-based PCC groups. Similarly, PCC patients without caregiver 
assistance may have increased ED use and hospitalization following discharge from index 
admission resulting in greater future costs,65,66 although evidence is mixed on the role of informal 
caregivers and acute care costs.66  
Religiosity, defined as strong religious beliefs, was not measured in the study but may have 
also contributed to outcome differences. Evidence suggests religiosity is associated with 
preferences for more treatment and life prolongation near EOL,67 while religious coping is 
associated with receipt of intensive life-prolonging medical care near death.68 African Americans’ 
higher religiosity,69 greater religious participation,70 and greater reliance on support from church 
communities70-72 are well-documented and may help explain why some utilization and cost 
outcomes did not differ among African American PCC and Non-PCC groups. African Americans’ 
faith influences how they perceive hospice and EOL treatments73 and greater deference to 
perceptions of God’s will in healthcare decision-making is associated with stronger preferences for 
life-prolonging treatment,74 possibly influencing our results. Although palliative care attends to the 
spiritual needs of patients, it is unknown if PCC reduces future acute care utilization in religious 
patients who do not enroll in hospice. And while African Americans’ trust in their physicians may 
not be a significant factor in ACP involvement or preference for EOL treatments,54 their greater 
dependence on church and community information when making healthcare decisions (compared 
to Whites who report primarily relying on healthcare providers)71 may help explain why many PCC 
outcomes differed for Whites but not African Americans.  
Race was not a factor in which patients received PCC in this medical center,6 but study 
results for African Americans may be partially explained by possible disparities in concordance 
between care preferences expressed during PCC and actual care received during subsequent 
hospitalizations. One urban, academic study found that despite similar rates of EOL discussions 
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among African American and White cancer patients, African American patients tended to receive 
life-prolonging measures at EOL even when they had DNR orders or stated a preference for 
symptom-oriented care.22 The study found EOL discussions helped White patients receive less life-
prolonging EOL care, but that African American patients did not experience the same benefits.22 
More research is needed to better understand why these differences exist and how clinicians can 
help prevent them to reduce racial disparities in the care of persons with serious illness. 
Intensive care unit utilization did not statistically differ between PCC/Non-PCC groups for 
either racial group when tiers were blended, suggesting some ICU care may be unavoidable.75 
Given nationwide increases in ICU use in the last 30 days of life among patients with serious 
illnesses76 and one study’s finding that 7% of ICU days are perceived as “futile,”77 and therefore 
modifiable by PCC, it is possible that (despite matching for characteristics at the time of index 
admission) differences in the necessity and futility of future ICU use may have differed among PCC-
race groups, also possibly contributing to cost findings among African Americans.78 
 Although acute care utilization and costs did not decline for African Americans with PCC, 
PCC was associated with a 15-fold increase in discharge to hospice among African American 
patients and a 14-fold increase among White patients. This is a remarkable finding given known 
racial/ethnic disparities in hospice use.51,54,79,80 These figures do not include hospice use among 
patients who may have learned of hospice during PCC, then enrolled in hospice weeks or months 
after discharge from index admission. In theory, future hospice use may be even greater among 
PCC patients. These increases in hospice use suggest patients who received PCC and were 
discharged to hospice may have benefited from improved quality of life and symptom 
management, reduced suffering, and for those who later died, possibly better quality of death.81 
PCC’s demonstrated ability to reduce racial disparities in hospice utilization make it an 
intervention worth expanding in populations with known differences in EOL care quality.  
Although the majority of African American PCC patients (60.1%) and White PCC patients 
(67.7%) changed their goals-of-care during index admission during or following PCC, there was a 
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significant difference among the PCC groups (P = 0.01), suggesting unmeasured factors may 
influence PCC outcomes (Table 3.1).  Even so, these high proportions suggest patient-provider 
PCC communication may have enabled patients make care decisions and may explain increases 
in hospice use across races and in DNR documentation (Table 3.6). Given that PCC has been 
shown to increase DNR documentation across racial groups, it is likely PCC in this study 
contributed to the increase in DNR orders.82 Although DNR orders do not always ensure patients 
receive care concordant with their expressed preferences, DNRs are associated with higher quality 
of life near death83 and reduced use of medical interventions near death,84 which may suggest 
lower costs, possibly influencing our study results. 
Finally, the comparison of outcomes across racial/ethnic groups of PCC patients highlights 
some important findings worth future investigation. Given racial disparities in hospice use,35,36 it is 
remarkable that significant differences in discharge to hospice were not found across PCC 
racial/ethnic groups. Significant differences were also not found across PCC race/ethnicity groups 
for changes in GOC, suggesting PCC is effective in enabling patients to communicate care 
preferences and supporting decisions to enroll in hospice across race/ethnicity groups. Palliative 
care consultations may therefore be an intervention that helps reduce racial/ethnic disparities in 
the care of persons with serious illness. Significant differences in future acute care costs and 
utilization, notably the number of days hospitalized, did exist across PCC race/ethnicity groups, 
implying the need for more research to better understand if and how PCC differs across 
racial/ethnic groups, and whether other unmeasured factors influence findings. 
Limitations 
 This study has several limitations. First, as is the case with all propensity-score studies, 
our models cannot account for unmeasured or unknown confounding variables.6,85 We were 
unable to control for comorbidities, income, insurance status, education level, health literacy, 
religious beliefs, or duration of survival because these variables were not available in the dataset; 
dates of patient deaths outside the health system were unavailable. Unmeasured variables may 
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be distributed differently in patients who received PCC and those who did not (e.g., patients in 
one group may have died sooner than patients in another after discharge).6  
In addition, diagnostic analysis of propensity score matching was not available, limiting 
understanding of how closely propensity tier groups matched on each of the ten specific 
variables. As with all propensity score matching studies with smaller samples, such as the PCC 
group in this study, it is difficult to perfectly match patients across a large number of variables.  
When comparing the two groups of patients (those who had PCC and those who did not) 
using propensity scores, the groups should have similar propensities for having had a consult.  As 
is standard, these propensities are determined through logistic regression models.  In this study, 
there were separate models for Caucasian patients and for African-American patients, but the 
methodological approach and variables used were similar. Each propensity model featured as its 
dependent variable whether or not an individual had a palliative care consult (yes or no) and ten 
predictor variables (gender, age, disease severity, primary diagnosis, Medicaid status, direct cost 
of index admission, visitation by Oncology team, ICU admission, ICU admission for more than 6 
days, and 30-day prior admission). Although patients in propensity-score matched PCC and Non-
PCC groups may look different when it comes to some of the matching variables, what is 
important is that the groups have similar propensities for having PCC. We used a tiered 
approach, where we cut the data into six evenly-sized groups (based on propensity scores) but 
eliminated the lowest four propensity groups because those groups did not have enough patients 
with high propensity for PCC. The two highest propensity score tiers, which were used to assess 
outcomes, matched very well—both tiers have essentially identical minimums and maximums and 
similar mean propensities, indicating the groups can be compared. The similarity of these specific 
values increases confidence in the analysis.  
Second, our analysis only examined acute care direct costs and healthcare utilization 
incurred within the health system after index hospitalization discharge.6 Our analysis did not 
include costs incurred between hospitalizations or outside the health system (e.g., outpatient 
 
 
86 
care, skilled nursing care, homecare) or ED visits that did not result in hospitalization. The health 
system is the largest acute care provider in the Northeast, so few patients were likely admitted to 
hospitals outside the system, but even so we were unable to track costs of patients who were 
readmitted to local hospitals outside the hospital system.6 Demographic and socioeconomic 
variables such as health literacy, religiosity, and marital status and clinical variables such as 
number of comorbidities, number of ED visits, and specific types of intensive interventions were 
unavailable in the dataset and therefore could not be analyzed. In addition, the variable 30-day 
readmissions only applies to patients still alive 30 days after discharge from index admission, 
which is not the entire sample population, as deaths among persons with serious illness occurred 
during the study period. Despite these limitations, study results may be used to show possible 
cost and utilization outcomes associated with PCC beyond the initial hospitalization among 
African Americans and among Whites in a sample matched, within racial group, on known 
covariates.5,6,8 
Finally, our study examined a single academic medical center with high acuity and a well-
established palliative care team and may not represent all hospitals caring for patients with 
serious illnesses. In the parent study at this medical center, race was not found to be a factor in 
whether or not patients received PCC.6 However, the researchers did not investigate whether 
future acute care cost and utilization outcomes differed by race/ethnicity when PCC access is 
similar. Our study used robust measurement strategies to fill this gap. Depending on resources, 
training, culture, and patient population, PCC may also affect patients differently in other 
systems.6 More research is needed to understand the influence of PCC on costs and healthcare 
utilization for specific racial/ethnic subgroups (e.g., Hispanics, Asians), which this analysis will be 
unable to address given smaller sample sizes for certain racial/ethnic populations. By studying 
the variable of race/ethnicity, our study provides more insight into future cost and healthcare 
utilization outcomes for African American patients who have or do not have PCC, and for White 
patients who have or do not have PCC while hospitalized. By comparing these outcomes among 
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propensity-matched White and African American patients with similar access to PCC, we were 
able to better understand associations between PCC and race/ethnicity on outcomes.  
Ethical Considerations 
Assessing acute care utilization and costs among different races raises ethical 
considerations. First, analyzing costs in the context of patient care may be perceived as a step 
toward rationing necessary healthcare among vulnerable persons. Although health systems 
benefit from reducing costs, saving money should never be the primary reason for engaging 
patients in PCC or making any clinical decisions.86 Clinical decisions should be made with patient 
goals in mind and intentions to provide patients high quality of care, quality of life, and quality of 
death—outcomes associated with EOL discussions11,81 and PCC.87,88  Costs represent the kinds 
of care patients receive, with high EOL costs associated with worse quality of death.12 Lower 
acute care costs represent less acute care utilization, which implies better quality of life for 
patients.12 Palliative care consultation offers patients, clinicians, and payers the opportunity to 
uniquely increase patient autonomy, improve quality of care and quality of death, and reduce 
resource use.89 Better communication about patient goals, values, prognosis, and treatment 
options benefits patients and tends to result in lower future acute care costs and admissions, 
benefiting patients and health systems alike. These mutual benefits clinically, financially, and 
ethically justify investment in PCC programs that aim to improve care for patients with serious 
illness. 
Second, the goal of any racial disparities research in healthcare is to reduce disparities 
and improve care and quality for disadvantaged racial minorities. The results of our study suggest 
there are unmeasured factors influencing future acute care utilization and costs among African 
Americans who received PCC. More research is needed to better understand which modifiable 
variables influence the effectiveness of PCC among African Americans and the concordance of 
care preferences and future actual care provided in both community and acute care settings. 
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The results of our study have implications for patients, clinicians, healthcare systems, 
payers, and policy makers in the United States and beyond. As healthcare systems seek to 
provide evidence-based, patient-centered, cost-effective quality care to racially diverse patient 
populations with serious illness, including those near EOL, PCC appears to be an intervention 
that reduces costs and saves resources overall while improving quality outcomes such as 
hospice use across races and additional outcomes among White patients. 
Conclusion 
This is the first known study to quantify PCC cost savings across hospitalizations by race. 
These cost-savings and reductions in acute care use among Whites and, directionally yet not 
significantly, among African Americans justify the development of PCC programs that help 
patients better understand their illness, prognosis, and care options; and support patients’ 
decisions to experience quality hospice care near EOL. Research is needed to explain why acute 
care utilization and cost disparities persist among African Americans despite PCC, and how 
clinicians can help overcome these disparities to provide high quality care for racial/ethnic 
minorities with serious illness.  
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CHAPTER FOUR: RISK FACTOR PROFILES ASSOCIATED WITH PALLIATIVE 
CARE CONSULTATIONS BEFORE DEATH 
 
Abstract 
Background: Previous studies show benefits of having early palliative care consultations (PCC) 
to discuss goals-of-care (GOC) with seriously ill patients. To help clinicians identify patients at-
risk for late PCC, it is important to understand risk factor profiles associated with the timing of 
these conversations in hospital settings where late conversations are more likely to occur. 
Objective: To identify risk factor profiles associated with the timing of inpatient PCC before death 
(0-14 days before death, 15-60 days before death, > 60 days before death) using available 
clinical, demographic, and administrative variables.  
Design: Secondary analysis of an observational, retrospective cohort study involving 
supplementary de-identified patient data.  
Sample and Setting: This study was conducted using preexisting clinical and administrative data 
from a large, urban, academic medical center in the Northeast region. Supplementary data 
(Medicaid status and days between PCC and death) was extracted from electronic medical 
records and matched to unique patient identifiers. The sample included 1,141 patients age 18+ 
who were admitted to the medical center, had PCC, and died between July 1, 2014 to October 
31, 2016 (PCC 0-14 days before death, n = 612; PCC 15-60 days before death, n = 292; PCC > 
60 days before death, n = 237). Patients who were admitted for childbirth or rehabilitation, and 
patients whose date of death was unknown were excluded.  
Measurements and Analysis: Adjusted multinomial logistic regression was used to identify 
variables associated with the timing of PCC. Variables included age, gender, race/ethnicity, 
Medicaid status, primary diagnosis, source of referral to palliative care, APR-DRG Severity of 
Illness (physiological decomposition), APR-DRG Risk of Mortality (likelihood patient will 
die), intensive care unit (ICU) use during index admission, ICU use greater than six days during 
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index admission, visitation by Oncology services during index admission, and source of referral to 
palliative care. Regression results were used to develop a Classification and Regression Tree 
(CART) model to identify risk factor profiles based on complex variable interactions associated 
with the timing of PCC before death. 
Results: Over half (54%) of patients received PCC “close to death” (0-14 days before death), 
26% received “moderately-timed” PCC (15-60 days before death) and 21% received “early” PCC 
(>60 days before death). The median PCC was 13 days before death. No evidence of 
multicollinearity was found among variables. Adjusted multinomial logistic regression identified no 
variables with significant differences across the three PCC timing groups overall. However, 
compared to patients over age 75, patients aged 56-60 were almost twice as likely to have 
consults close to death relative to early (OR = 1.94, 95% Confidence Interval 1.09, 3.47; P=0.03), 
with no significant difference for moderately-timed PCC relative to early. Compared to referrals 
from Oncology specialists, patients referred to PCC by General Medicine/Hospitalists were twice 
as likely to have consults close to death relative to early (OR = 2.02, 95% Confidence Interval 
1.16, 3.53; P = 0.01), with no significant difference for moderately-timed PCC relative to early. 
The CART model was effective at identifying which patients received PCC 0-14 days before 
death (88.2% sensitivity), but not which patients received PCC 15-60 days before death (27.4%) 
or PCC > 60 days before death (1.7%). The model was effective at identifying which patients did 
not receive early or moderately-timed PCC (specificity 99.1% and 82.1%, respectively). Patients 
with extreme illness severity who were in the ICU and were Hispanic or “Other” racial/ethnic 
minority were more likely to receive PCC close to death (85%); age under 46 or older than 75 
further increased this probability (98%). On the other hand, patients with non-extreme illness 
severity who were not in the ICU were least likely to receive PCC close to death (24%). ICU 
patients with extreme illness severity were more likely to receive PCC close to death (64%), but 
50% of ICU patients with less than extreme severity of illness also received PCC within 14 days 
of death.  
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Conclusion: In this secondary analysis, a majority of patients with serious illness (e.g., cancer, 
cardiovascular disease, etc.) received PCC close to death. A complex set of variable interactions 
were associated with the timing of PCC. A systematic process for engaging patients with PCC 
earlier in the care continuum, and especially in the ICU regardless of illness severity, is needed.  
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Introduction 
As medicine and technology advance and providers are able to alter the normal dying 
process with life-extending treatments, patients with serious illness and their families are 
increasingly tasked with making difficult decisions about end-of-life (EOL) care.1 Although less 
aggressive EOL care is often preferred2-4 and is associated with family perceptions of higher 
quality care and lower regret,5,6 hospitals’ default mechanism to maintain life often results in 
patients receiving intensive, sometimes unnecessary, care near death.7 Evidence suggests a 
majority of patients receive intensive care unit (ICU) treatment within six months of dying8 and up 
to 38% of patients receive non-beneficial treatments near EOL, which may alter quality of life.7 
Patient-provider discussions about goals-of-care (GOC) and EOL, including 
conversations that occur during palliative care consultations (PCC), enable providers to 
understand patient values and needs, help patients make informed decisions about their care 
experience before dying,9 and are associated with patients receiving the kind of care they prefer 
at EOL.10-12 Patients who have PCC are almost seven times more likely to document advance 
care planning wishes than patients who do not have PCC,13 which may further help achieve care 
concordant with preferences.11,14 These conversations are also associated with less aggressive 
treatments and lower use of intensive care, 9,11,15-18 lower 30-day readmission rates and 
hospitalizations overall,9,16,17,19 fewer in-hospital deaths and greater utilization of hospice, 10,15-18,20 
and higher quality EOL care.18,21 Perhaps as a result of supporting patients who choose less 
aggressive care near EOL, these discussions are also associated with lower EOL costs,16,22-27 
which evidence suggests is associated with better quality of death.17 When patients have these 
important discussions and receive the EOL care they prefer, lower costs often follow, benefiting 
patients and health systems alike.28 
Palliative care consultations offer many communication and clinical benefits, such as 
improving pain and symptom management and increasing advance care planning,16,22,24-26,29-32 
but the timing of these consultations matters.33-37 Earlier care planning conversations are 
associated with greater quality of life near EOL and may help patients receive care more 
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consistent with preferences.18,21,38,39 Later GOC discussions are associated with greater risk of 
aggressive care, hospital death, and odds of ICU admission.18 Specifically, PCC < 90 days before 
death—timing that most typically occurs in hospital settings—is associated with higher rates of 
inpatient, ICU, and emergency department care in the last month of life, and higher direct 
inpatient costs in the last six months of life ($6,687 difference per person) compared to PCC 
occurring more than 90 days before death.36 Higher EOL costs reflect greater use of acute and 
intensive services, which are associated with worse quality of death.17 If care planning and EOL 
discussions occur close to death, patients may make pressured decisions leading to care that is 
not concordant with their preferences.15,40,41  
In one study of advanced heart failure patients, PCC to discuss GOC during terminal 
hospital admission was often either absent or very near death, with a median time of six days 
between PCC and death and only 24 hours between orders for comfort care and death.42 The 
timing is not much better among persons with other serious illnesses.12 Patients with cancer 
experience the most timely consultations, a median of 16-33 days before death depending on 
cancer type and other factors.15,43,44 Each additional day from hospital admission to care planning 
conversation has been found to be associated with a 4% increased risk of aggressive 
interventions and in-hospital death, and 19% greater odds of intensive care unit (ICU) 
admission.18 Early discussion of prognosis and EOL care options facilitates earlier enrollment in 
hospice and earlier use of palliative care services,45 which are associated with quality care.33,46 
When care planning discussions occur close to death, or not at all, patients may not receive the 
benefits of comfort care as early as they might have liked, possibly resulting in greater regret 
about care decisions.6 Evidence suggests racial/ethnic minorities are less likely than Whites to 
have these conversations with healthcare providers,47-52 but for minority patients who do have 
these conversations, such as during PCC in which race may not be a factor,16 little is known 
about their timing. Unfortunately, 84% of patients who receive PCC less than 90 days before 
dying have their consultations inpatient while hospitalized,36 limiting the time palliative care teams 
have to refer patients to services that enhance their quality of life.35 Despite the benefits of having 
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early PCC37,53,54 and GOC1,55 conversations, little is known about risk factor profiles associated 
with the timing of these conversations in hospital settings where late conversations are more 
likely to occur.  
The main aim of this study is to identify risk factor profiles associated with patients 
receiving palliative care consultations for GOC (hereafter called “PCC”) 0-14 days before death 
(“PCC close to death”), 15-60 days before death (“moderately-timed PCC”), and more than 60 
days before death (“early PCC”).  
The timing categories are based on Medicare hospice data, which shows 41% of patients 
on hospice received 0-14 days of care (28% received seven or fewer days of care, presumably in 
the last week of life), 26% received 15-60 days of care, and 33% received more than 60 days of 
hospice care.45 Hospice care is associated with family perceptions of excellent quality EOL care 
and greater concordance between patient wishes and EOL care, with the highest quality EOL 
outcomes associated with patients receiving hospice for more than 30 days.46 Evidence suggests 
efforts to decrease ICU admissions near EOL, decrease hospital deaths, and increase earlier 
hospice enrollment may improve the quality of EOL care.5 Earlier PCC also allows for more 
opportunities to discuss treatment decisions and advance care planning,35 topics in PCC that are 
associated with reduced hospitalizations near death and increased use of hospice.54 Better 
understanding risk factors associated with PCC timing may help clinicians initiate these 
discussions earlier with patients at risk for having late conversations and enable patients to make 
decisions that result in high quality EOL care consistent with preferences.  
To further understand associations between PCC timing and other outcomes, the 
secondary aims of this study are to describe discharge to hospice from index admission, 
presence of do-not-resuscitate (DNR) documentation during index admission, whether patients 
changed their GOC during index admission, and median EOL acute care costs (defined as direct 
acute care costs incurred in the health system during and following index hospital admission to 
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the point of death). Index admission is defined as the hospitalization in which PCC first occurred 
during the study period (Appendix A).16 
Methods 
Study Design  
This secondary analysis was designed to identify risk factor profiles associated with the 
timing of PCC before death (0-14 days, 15-60 days, and greater than 60 days before death) 
among patients who received inpatient PCC at an academic medical center. Supplementary data 
from the medical center’s electronic record database (Medicaid status and days between PCC 
and patient death) was matched to unique patient identifiers. 
Dataset 
Setting. Our analysis used data from a study conducted at a 776-bed, urban, academic 
medical center in the Northeast region.16 The medical center serves a socioeconomically and 
racially diverse area of patients, composed of African Americans (46%), Whites (36%), Asians 
(9%), and Hispanics (6%).56 In addition, the medical center receives a significant number of 
patients transferred from other hospitals in the region, including hospitals that serve 
predominantly White patients from areas with higher median incomes and education levels. The 
palliative care team at this medical center is well-established and predominantly operates as a 
consultation service. The team includes physicians, advance practice nurses, registered nurses, 
social workers, a pharmacist, and a chaplain.16 Two-thirds of the team’s consultations involve 
GOC discussions.16 
Data. The dataset includes demographic, clinical, and financial cost information tied to 
each patient’s healthcare utilization in the medical center during the study period (July 1, 2014 to 
October 31, 2016). The medical center’s palliative care registry was used to identify all patients 
who received PCC specifically to discuss GOC during the study period. Consultations about pain 
or symptom management, psychosocial or spiritual distress, or transition planning that did not 
involve GOC discussion were excluded.  
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Sample. Our study included patients 18 and over who were admitted to the medical 
center between July 1, 2014 and October 31, 2016 (the study period), received PCC, and died 
during the study period. Patients were included if they died in the hospital system while on 
hospice or not on hospice, died outside the hospital system while on hospice, or died outside the 
hospital system not on hospice but had been seen by a provider affiliated with the medical center 
who updated the patient’s medical record to reflect their death. Patients who were admitted for 
childbirth or rehabilitation were excluded, as were patients who died in community hospitals 
whose deaths were not updated in the medical center’s records. 
Data privacy and security. This study was approved by the University of Pennsylvania’s 
Institutional Review Board, which granted the current study an exempt status (45 CFR 46.104, 
category #4). The investigators followed University of Pennsylvania procedures for ensuring 
patient data privacy and security. Prior to the transfer of data, all patient data was de-identified to 
ensure privacy and compliancy with the Health Insurance Portability and Accountability Act 
(HIPAA). Without sharing dates of initial PCC or dates of patients’ deaths, the health system’s 
director of analytics provided the number of days between initial PCC and patient death, ensuring 
patient privacy while allowing analysis to be unaffected by blinding. Age was provided in 
categorical groups to further protect patient identity. De-identified data was transferred through 
SecureShare, an internet-based application for securely exchanging files, and saved to a secure, 
encrypted folder on the University of Pennsylvania School of Nursing’s firewall-protected network 
drive. Accessing the folder and the network drive requires two-step authentication. The network 
drive that contained the data is routinely monitored for system and security breaches. Only study 
investigators and approved personnel, had access to the de-identified study data.  
Measures 
Timing of palliative care consultations for goals-of-care. The primary outcome of interest 
is time between a patient’s first inpatient PCC during the study period and patient death, 
categorized into three non-overlapping levels of data: PCC close to death, defined as 0-14 days 
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before death; moderately-timed PCC, defined as 15-60 days before death; and early PCC defined 
as more than 60 days before death. The date of first PCC during the study period was used to 
calculate days between first PCC and patient death (Appendix A). Although the literature 
suggests early palliative care referral may be defined as more than 90 days before death,36 
consultations occurring in that timeframe predominantly occur in outpatient settings.36 Because 
this study focuses on GOC conversations occurring during inpatient hospitalization, the time 
parameters are shorter and were defined with other inpatient GOC studies in mind.15,57  
Risk factors for profiles associated with the timing of PCC. Correlates included 
sociodemographic data such as age, gender, self-reported race/ethnicity, and Medicaid status; 
and clinical variables such as primary diagnosis at the time of index hospitalization discharge 
based on diagnosis-related group (DRG), All-patient refined DRG (APR-DRG) severity of illness 
(the extent of physiologic decomposition, determined at index hospitalization discharge), APR-
DRG risk of mortality (the likelihood a patient will die, determined at index hospitalization 
discharge), whether a patient had any ICU care during the index admission, whether a patient 
had ICU care for more than six days during the index admission (to indicate high acuity), whether 
a patient was visited by an Oncology team during the index admission, source of referral to 
palliative care (e.g., Oncology), and acute care utilization in the 30 days before index admission 
(Table 4.1).  
APR-DRG severity of illness and APR-DRG risk of mortality are assigned to a patient 
based on the diagnoses and procedures coded for billing during the hospitalization, and have four 
subcategories (minor, moderate, major, extreme) that are assigned by health system software 
designed to assess patient risk and resource allocation.16,58,59  These measures take into account 
a patient’s comorbidities and the stage and interaction of those diseases.59 High scores are 
characterized by multiple serious illnesses and interaction among those illnesses, and are a 
reliable proxy for comorbidities.60  
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Descriptive variables associated with PCC timing. Discharge to hospice from index 
admission, DNR documentation during index admission, whether patients changed GOC during 
index admission, and EOL acute care costs (direct acute care costs incurred in the health system 
during and following index hospital admission to the point of death) are described (Table 4.1).  
Statistical Methods 
Descriptive statistics and measures of central tendency were used to characterize the 
variables and describe the sample based on timing of PCC before death (SAS v. 9.4, SAS 
Institute Inc., Cary, NC) (Table 4.1). Chi-squared tests were performed to examine associations 
between categorical variables. Kruskal-Wallis tests and analysis of variance (ANOVA) tests were 
performed for the distributions of continuous measures by PCC timing, as appropriate. There 
were minimal missing data in the dataset. Specialist referral data was missing for one patient. 
This patient was included in the study. (In the parent study, 0.4% of patients were excluded due 
to missing data.)  
To inform development of the classification and regression tree (CART) model, an 
adjusted multinomial logistic regression model was built using all available, clinically meaningful 
independent variables (Stata v. 15, StataCorp, College Station, TX) (Table 4.2). Odds ratios were 
calculated across variables using early PCC as the reference group. Classification and regression 
tree modeling was then applied with SAS JMP software using all clinically meaningful variables, 
regardless of significance demonstrated in the multinomial logistic regression model (Figure 4.1). 
Risk of mortality is known to be a strong correlate of the PCC timing because it increases as a 
patient nears death.61 To better understand the interaction of other variables, risk of mortality was 
excluded from the model. The CART model shows how independent variables, or risk factors, 
interact to create associations with the outcome of PCC timing.62  
For CART modeling, the dataset was divided into training (N = 571), validation (N = 285), 
and test (N = 285) sets. In training the decision tree, CART analysis software recursively divided 
the training data one variable at a time to generate a series of splits that best identified the 
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outcome of PCC timing.63 CART software chooses where to split variables based on where the 
division most accurately homogenizes the outcome variable while minimizing the model’s 
misclassification rate, a process that results in subgroups more homogenous in the outcome of 
PCC timing than the original sample.62,64 Specifically, splitting occurred when the decrease in 
entropy was less than 9.5. We then selected the tree with the most clinically meaningful patient 
profiles. The test set was used to evaluate performance of the decision tree. Traditional statistical 
power analyses do not apply to CART modeling,65,66  but our sample was sufficient for running 
complex interactions because it was greater than the minimum 100 participants that is 
recommended.66 
Results 
Timing of PCC. The sample included 1,141 patients who received inpatient PCC prior to 
dying during the study period. Over half of patients received PCC 0-14 days before death (53.6%, 
n = 612); 25.6% received PCC 15-60 days before death (n = 292); and 20.8% received PCC 
more than 60 days before death (n = 237). Overall, patients had PCC a median of 13 days before 
death. Patients in the early PCC group received PCC a median of 135 days before death, 
patients who had PCC 15-60 days before death had it a median of 28 days before death, and 
patients in the PCC group close to death received PCC a median of 5 days before death (P < 
0.0001). Over half (54%) of patients in our sample received PCC within two weeks of dying, 26% 
received PCC 15-60 days before death, and only 21% received PCC more than 60 days before 
death.  
  Correlates of the timing of PCC before death. Table 4.1 presents the distribution of 
potential risk factor variables based on the timing of PCC before death. Variance Inflation Factor 
was less than three for all variables, indicating no evidence of multicollinearity among variables. 
Results of the adjusted multinomial logistic regression (Table 4.2) were limited, suggesting other 
variables not measured in this study may be associated with the timing of PCC before death. 
Small sample sizes within groups may also have contributed to this finding. There were no 
statistically significant differences among the three timing groups overall, but some differences 
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were significant between groups. For example, compared to patients over age 75, patients aged 
56-60 were found to be almost two times more likely to have consults close to death than early 
(OR = 1.94, 95% Confidence Interval 1.09, 3.47; P = 0.03), with no significant difference for 
moderately-timed PCC relative to early. Compared to patients with cancer, patients in “other” 
diagnoses category were less likely to receive a moderately-timed consult than early consult (OR 
= 0.47, 95% Confidence Interval 0.22, 0.10; P = 0.049) and, although not significant, less likely to 
have PCC close to death (OR = 0.53, 95% Confidence Interval 0.28, 1.01; P = 0.052) compared 
to early. Patients with “Other” category had primary diagnoses such as skin conditions and ulcers, 
musculoskeletal conditions, psychiatric disorders, traumatic injuries, or postoperative or 
procedure-related conditions. These conditions were combined into the “Other” category due to 
smaller sample sizes. Finally, compared to referrals from Oncology specialists, patients referred 
to PCC by General Medicine/Hospitalists were two times more likely to have consults close to 
death (OR = 2.02, 95% Confidence Interval 1.16, 3.53; P = 0.01), with no significant difference for 
moderately-timed PCC compared to early.  
Decision tree model identifies profiles of patients associated with receiving PCC close to 
death. As shown in Table 4.3, the CART model had 54.7% accuracy identifying the PCC timing 
outcome (CI 48.8%, 60.6%), which was similar to the predictive error in the test data (53.7%). 
The overall identification accuracy did not improve significantly, likely because the model was 
only able to accurately identify patients who received PCC close to death (model sensitivity for 
PCC close to death was 88.2%). The model’s specificity for PCC close to death was 32.6%, 
which indicates the model less accurately identified patients who did not have PCC 0-14 days 
before death. Although the model demonstrated poor ability to identify patients who had early 
PCC or moderately-timed PCC (sensitivity 1.7% and 27.4%, respectively), the model effectively 
identified which patients did not receive early or moderately-timed PCC (specificity 99.1% and 
82.1%, respectively)—timing that is preferable to PCC close to death. In short, the model was not 
effective at identifying which patients received moderately-timed (n = 147) or early PCC (n = 118), 
but it was effective at identifying which patients received PCC close to death (n = 306) and which 
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patients did not receive early or moderately-timed PCC. Smaller sample sizes, particularly for 
early and moderately-timed PCC groups, may have contributed to these findings.  
Risk factor profiles associated with patients likely to receive PCC close to death. Figure 
4.1 illustrates the CART model’s identification of patients most likely to receive PCC 0-14 days 
before death compared to moderately-timed and early PCC. In the model’s depiction of complex 
interactions associated with PCC timing profiles, severity of illness was found to be the most 
important variable, followed by ICU use, age, primary diagnosis, race/ethnicity, use of Oncology 
services, and hospitalization 30 days prior to index admission. Severity of illness was highly 
associated with PCC timing: 64% of patients with extreme illness received PCC close to death. 
Only 13% of patients with extreme illness and 35% of patients with less than extreme severity of 
illness received PCC more than 60 days before death, indicating opportunities to discuss GOC 
earlier with patients. ICU use during index admission further increased probability of association 
with PCC timing. ICU patients with extreme illness severity were more likely to receive PCC close 
to death (64%). Although representing a lower probability, a staggering 50% of ICU patients with 
less than extreme severity of illness also received PCC within 14 days of death. Patients with 
extreme illness severity who were in the ICU and were Hispanic, “Other” racial/ethnic minority 
(American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or “Other” race/ethnicity), or 
did not disclose their race/ethnicity  were more likely to receive PCC close to death (85%); age 
under 46 or older than 75 further increased this probability (98%). Non-ICU patients with extreme 
severity of illness, no hospital admission in the previous 30 days, and a primary diagnosis of 
cancer, other cardiovascular disorders, endocrine disorders, GI disorders, gynecological or 
urological disorders, blood disorders, infectious disease, sepsis, musculoskeletal disorders, or 
neurologic disorders had a 58% probability of PCC close to death—a probability (96%) that 
dramatically increased if the patient was also age < 40 or  > 75.  
On the other hand, patients with non-extreme illness severity who were not in the ICU 
were less likely to receive PCC close to death (24%). Non-ICU patients with extreme illness 
severity with conditions other than heart failure, respiratory disorder, or “Other” condition who did 
 
 
126 
not receive Oncology care during index admission but had been admitted to the hospital 30 days 
prior also demonstrated low probability for PCC close to death (19%). Finally, non-ICU patients 
with extreme severity of illness who had heart failure, a respiratory disorder, or “Other” diagnosis 
had the lowest probability of PCC close to death (17%) and high probability for early PCC (80%). 
It is unknown if this is a case of reverse causation or if other factors are involved.   
Findings of the secondary aims. During index admission, patients spent a median 11 
days hospitalized (IQR 6-22 days, P < 0.0001), 3 days in the ICU (IQR 0-11 days, P < 0.0001), 
and incurred median direct acute care costs of $26,005 (IQR $12,908-$59,889; P = 0.18; and 
mean costs of $51,000, SD $93,302; P  = 0.02). Index admission utilization and costs were 
generally greatest among patients who received PCC 0-14 days before death. PCC groups 
differed in age (P = 0.04), race/ethnicity (P  = 0.02), primary diagnosis (P = 0.006), severity of 
illness (P < 0.0001), risk of mortality (P < 0.0001), ICU care during index admission (P < 0.0001), 
ICU care greater than 6 days during index admission (P < 0.0001), and whether they had been 
visited by the Oncology team during their index admission (P = 0.03). About 80% of PCC patients 
changed their GOC during PCC, with rates increasing the closer a patient was to death (P < 
0.0001). Do-not-resuscitate (DNR) documentation also increased the closer a patient was to 
death (early PCC 26%, PCC 15-60 days 59%, PCC close to death 86%, P < 0.0001), with 67% of 
the total sample having resuscitation wishes documented during index admission. It is unknown if 
DNR documentation occurred before or after PCC. 
Discussion 
 The CART model effectively identified factors associated with PCC 0-14 days before 
death, making it a useful tool for identifying vulnerable patients at risk of PCC close to death, and 
provided insights into patient populations likely to receive PCC 15-60 and > 60 days before death. 
In addition, the model effectively identified which patients did not receive early or moderately-
timed PCC, which enables clinicians to identify and target patients who are not getting more 
optimally-timed, beneficial consultations, and develop interventions that better support such 
patients’ needs. The model was not able to accurately identify which patients received early or 
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moderately-timed PCC, possibly because relatively few patients received early PCC and because 
already small sample sizes for these groups diminished in the context of variable interactions. It is 
also possible variables not included in our model may have improved the model’s ability to 
identify patients likely to receive moderately-timed or early PCC. Given that more than half the 
patients in the sample died within 14 days of receiving PCC and only one-fifth received PCC 
more than 60 days before death, this study illuminates a critical need for clinicians to engage 
patients with serious illness in PCC discussions about GOC earlier in the illness trajectory. 
Patients in our study received PCC a median 13 days before death, which is less than the 
national median length of hospice care (24 days)67 and cancer studies that show median times 
ranging from 16-33 days between PCC and death.15,43,44  
 Among complex interactions identified by CART modeling, ICU utilization was found to 
be the second greatest contributor to risk factor profiles associated with PCC timing. Intensive 
care during index admission for patients with extreme severity of illness contributed to a 67% 
probability of PCC close to death (and 50% probability of PCC close to death for all other ICU 
patients), suggesting the importance of coordinating PCC for patients in the ICU regardless of 
illness severity. This finding is consistent with evidence-based recommendations to involve PCC 
when caring for patients in the ICU.28,68 One recent study found patients in the neuro-ICU who 
received PCC were more likely to change GOC to less invasive care, receive fewer procedures in 
the last 48 hours of life, and receive better symptom management.69 Another study found 
involving PCC in the ICU increased advance care planning and decreased use of aggressive 
interventions.70 Consulting palliative care earlier in the ICU stay gives patients and families more 
time to benefit from GOC discussions and the improvements in symptom and care management 
that follow. Because all ICU patients can benefit from PCC, research into systematic processes 
for involving PCC early in the ICU admission, such as those developed using evidence-based 
triggers and machine learning, are recommended.68,71,72 Early evidence suggest systematic 
processes increase PCC in the ICU,71 possibly reducing disparities that result from referral-driven 
care.  
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A more systematic process for involving PCC in the care of patients with serious illness 
may also help reduce racial/ethnic disparities in EOL care. It is unknown why ICU patients who 
self-identified as Hispanic or other racial/ethnic minority demonstrated such a high probability for 
receiving PCC close to death. Hispanics and other racial/ethnic minorities endure disparities in 
access to care and experiences throughout the care continuum that may influence when they first 
receive PCC.73-79 For example, providers are less likely to have EOL discussions55 and less likely 
to discuss prognosis80 with Hispanics and other racial/ethnic minorities, possibly influencing their 
health literacy and receptivity to PCC.76 Other factors such as religiosity, family dynamics, and 
socio-cultural preferences may also contribute to PCC timing.76,79,81 More research is needed to 
better understand barriers to earlier PCC with severely ill Hispanics and other racial/ethnic 
minorities, and how clinicians can overcome such barriers to better support racial/ethnic 
minorities with serious illness.73-75 Improved communication and earlier involvement with PCC 
may help reduce the disparities in EOL care and costs documented among Hispanic patients and 
other minorities.17,73,81-83 
The model found only 17% probability that non-ICU patients with extreme severity of 
illness who were admitted for heart failure, a respiratory condition, or a condition not otherwise 
listed (e.g., pressure ulcers, musculoskeletal conditions) had PCC close to death. According to 
CART, these patients had 80% probability of having early PCC. Patients with advanced heart 
failure and respiratory disorders such as chronic obstructive pulmonary disease have different 
illness trajectories than, for example, patients with cancer. The patterns of organ failure 
associated with conditions like heart failure cause patients to be hospitalized during acute crises 
from which they may recover. Patients who recover after receiving PCC during a disease 
exacerbation may partially compose the early PCC group. Research is needed to better 
understand which patients receive PCC early and why.  
Over half the patients who had PCC more than 60 days before death changed their GOC 
during PCC, suggesting the relevance and appropriateness of earlier conversations. The 
proportion of patients who changed their GOC during PCC increased the closer a patient was to 
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death, as did DNR documentation. Had patients engaged in these discussions earlier, they may 
have chosen to change their care goals earlier and may have benefitted from greater time 
receiving care consistent with their preferences. Health systems seeking to manage costs may 
also benefit from offering patients earlier PCC. Despite having significantly more days to accrue 
costs before death, as measured in our study, patients with earlier PCC had only $8,993 greater 
median acute care EOL costs than patients who had PCC within 14 days of dying. Other 
evidence suggests that early PCC appears to mediate the increase of inpatient costs toward EOL 
observed among patients who receive late PCC,36 but more research is needed to understand the 
monetary effect each day before death PCC has on EOL acute care costs. 
This medical center treats a high number of severely ill patients transferred from other 
hospitals within the region, which may have contributed to the majority of patients receiving PCC 
close to death. Although timing improvements can be made in acute care settings using 
systematic triggers for inpatient PCC among eligible patients,71,72,84-86 poor access to PCC in the 
community likely contributes to late timing. Increased access to community-based palliative care 
models would improve the time between PCC and death, enable patients to benefit from palliative 
care longer,36,87 and help meet patient needs throughout the care experience and not just during 
inpatient hospitalizations.88,89  
Limitations 
This study is limited in a few ways. First, given the secondary nature of the study, a 
limited number of variables were available to assess. We were unable to assess other relevant 
confounders such as socioeconomic variables (e.g., health literacy, income, or education level), 
or religious and cultural beliefs. Due to the observational nature of the study, some unavailable 
variables may be salient in risk factor profiles associated with the timing of PCC or be important 
confounding factors, influencing results. Fortunately, the study was able to assess Medicaid use, 
which can be considered a proxy for socioeconomic variables because its eligibility is based on 
income. In addition, the index PCC may have occurred before some of the correlates, such as 
 
 
130 
ICU admission or the assignment of severity of illness or risk of mortality, making conclusions 
about chronology unfeasible but still resulting in relevant insights. 
Second, our study does not include patients whose date of death is not recorded in the 
health system database. Patients who received PCC but whose death information is not available 
may have had shorter or longer durations between consultation and death. As such, the variables 
we measured may be distributed differently across the three groups and may be associated with 
timing differently. Given that 64% of the patients who received PCC in the parent study died 
during the study period, and that not all patients are likely to have died during the study period, 
our sample may include most patients who died during the study period. Unfortunately, we were 
unable to differentiate between patients who died within the health system and those who died 
outside the health system but whose death information was updated by providers affiliated with 
the medical center (e.g., specialty physicians in an outpatient setting). We were unable to assess 
any differences in demographic or clinical factors between patients whose deaths occurred in-
system versus those whose deaths occurred outside the system. If there were differences in 
these sub-populations, we were unable to account for them in our analysis.  
Finally, our study examined a single academic medical center with high acuity and a well-
established palliative care team located in an area with significant racial, ethnic, and 
socioeconomic diversity. As such, the medical center may not represent all hospitals caring for 
patients with serious illnesses, possibly limiting generalizability of results. Willingness to engage 
in GOC/EOL conversations and referral patterns to PCC may differ in other systems. Despite 
these limitations, our study results increase understanding of risk factor profiles associated with 
the timing of inpatient PCC, including how race/ethnicity are associated with the timing of GOC 
discussion. 
Ethical Considerations 
Given PCC’s association with less aggressive care and higher quality of life, and its role 
in patient and family informed decision-making, identifying patients at risk for late consultation is 
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an ethical priority. All patients should be given time to adequately understand prognosis and 
consider care options, but our research shows the majority of patients receive consultation within 
two weeks of dying and that disparities exist. The interaction of illness severity, ICU care, and 
race/ethnicity suggests a need for more culturally effective care of seriously ill patients from 
diverse backgrounds and a need for a more systematic process that integrates PCC across the 
care continuum. Patients and families cannot reap the benefits of earlier palliative care if policies 
and payment schemes do not support palliative care delivery in the community. New policies, 
payment models, and innovative workforce models involving trained nurses and primary care 
providers are needed to ethically and effectively deliver palliative care earlier to patients with 
serious illness.  
Conclusions 
The majority of patients with serious illness who had PCC before dying did so within two 
weeks of death, which may not be enough time to make decisions that result in the kind of death 
and dying experience patients and families desire. A complex set of factors was associated with 
PCC timing. Regardless of illness severity, ICU care is associated with patients receiving PCC 
close to death, suggesting the need for systematic PCC across ICU patient populations. 
Racial/ethnic disparities persist in the timing of PCC for extremely sick Hispanic and other 
racial/ethnic minorities, making it an ethical priority to provide earlier, culturally-effective care and 
communication to racial/ethnic minority patients. Timely communication of patient goals, values, 
and EOL preferences should start in the community before inpatient hospitalization when late 
PCC is likely to occur. Innovative care and payment models, policies, and workforce solutions are 
needed to support earlier integration of palliative care in acute and community settings. 
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Table 4.3 Classification and Regression Tree (CART) model performance for identifying profiles 
associated with the timing of palliative care consultation for goals-of-care before death 
 
Sample Statistic Value 
PCC patients who died 
during the study period  
Root node error 0.537 
Accuracy (95% Confidence Interval) 0.547 (0.488, 0.606) 
P-Value [Acc >NIR] 0.384    
Patients with PCC  
0-14 days before death 
Sensitivity  0.882  
Specificity 0.326 
Positive predictive value  0.603 
Negative predictive value 0.705 
Patients with PCC  
15-60 days before death 
Sensitivity 0.274 
Specificity  0.821 
Positive predictive value  0.345 
Negative predictive value 0.767 
Patients with PCC  
> 60 days before death 
Sensitivity  0.017 
Specificity  0.991 
Positive predictive value  0.333 
Negative predictive value 0.794 
 
*The P-value represents the probability that model accuracy is higher than the no information rate 
(NIR). Sensitivity represents the proportion of patients correctly identified in the model as having 
had PCC in the associated timeframe. Specificity represents the proportion of patients that did not 
have PCC in the associated timeframe and were correctly identified in the model. Positive 
predictive value is the proportion of patients who actually received PCC in the associated 
timeframe out of all patients identified in the model as having received PCC in that timeframe. 
Negative predictive value is the proportion of patients who actually did not receive PCC in the 
associated timeframe out of all those identified in the model as having not received PCC in that 
timeframe.  
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CHAPTER FIVE: DISCUSSION AND CONCLUSIONS 
Introduction 
The United States spends more money on patients in the last year of life than any 
country in the world.1  This high spending does not necessarily reflect higher quality EOL care 
compared to other developed countries, but instead reflects greater use of intensive and acute 
care at EOL.2-4 Aggressive EOL care is not only significantly more expensive than less 
aggressive care,5 it is also associated with lower quality EOL care6-8 and higher decision regret 
among families.9,10 Evidence suggests most patients do not prefer aggressive EOL care.11-15 This 
incongruity between care preferences and EOL practices may be mitigated by EOL discussions 
about care preferences led by trained professionals, including palliative care consultation (PCC) 
teams.  
Patient-provider discussions about end-of-life (EOL) and goals-of-care (GOC), including 
those that occur during PCC, enable patients to ask important questions, express their 
understanding of the terminal nature of their illness, and communicate what is important to them 
as they near EOL. Understanding a patient’s values, goals, and care preferences enables 
clinicians to provide care concordant with expressed desires,16-18 allowing vulnerable patients to 
have more of the dying experience they want. These critical conversations are associated with 
less aggressive, less intensive care near EOL,2,13,17,19-21 which in turn is associated with higher 
quality EOL care6-8 and lower regret for EOL treatment decisions.9,10 End-of-life and GOC 
discussions are also associated with lower acute care costs near death, with early evidence of 
savings ranging from $6,000 to $9,500 per patient.2,21,22 Lower EOL costs are associated with 
better quality of death,2 making the exploration of EOL costs and communication an ethical 
necessity. End-of-life discussions and PCC mutually benefit patients and health systems: patients 
who have these conversations appear to experience a higher quality dying experience more 
consistent with values and preferences, and health systems incur lower costs as a result.2,23  
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African Americans and other racial/ethnic minorities in the United States are less likely to 
have important EOL care planning discussions with their healthcare providers24-30 and are more 
likely to receive intensive, life-prolonging EOL care compared to Whites.24,31-36 They are also 
reported to have higher EOL costs,31 which may contribute to a lower quality dying experience.2 
In its groundbreaking report (2015), Dying in America, the National Academy of Medicine called 
for more research into racial/ethnic disparities in EOL care,37 but costs studies have been limited 
to date. In fact, evidence about EOL discussions, including those occurring during PCC, and 
future healthcare utilization and costs has been especially limited in the context of race/ethnicity 
and the timing of conversations.  
Overall Goals 
To fill gaps in the literature, this dissertation achieved the following goals: it explored 
associations among EOL discussions, healthcare utilization, place of death, and costs in persons 
with advanced cancer near EOL (Aim 1, Chapter 2); assessed future acute care costs and 
healthcare utilization following palliative care consultation to discuss GOC or EOL (hereafter 
called “PCC”) among Whites and African Americans with serious illness who either did or did not 
have PCC (Aim 2a, Chapter 3); described acute care utilization, costs, and discharge to hospice 
among racial groups who received PCC (Aim 2b, Chapter 3); examined risk factor profiles for 
PCC 0-14 days before death (“PCC close to death”), 15-60 days before death (“moderately-timed 
PCC”), and greater than 60 days before death (“early PCC”) among deceased persons with 
serious illness who had PCC prior to dying (Aim 3a, Chapter 4); and described EOL acute care 
costs, changes in GOC, DNR documentation, and discharge to hospice from a hospitalization 
with PCC among deceased patients (Aim 3b, Chapter 4). These objectives were achieved 
through a systematic review of the literature (Aim 1); a propensity-matched cohort study of 
secondary data from a large, urban, academic medical center (Aim 2); and multinomial logistic 
regression models and classification and regression tree analysis of decedents who received 
PCC from the same dataset (Aim 3).  
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 The systematic review presented in Chapter 2 revealed significant variations in how 
researchers and clinicians define advance care planning (ACP) and EOL discussions, and in how 
they conceptualize and measure care outcomes. It also showed a gap in research exploring EOL 
discussions and acute care costs, which this dissertation sought to help fill. Chapter 3 identified a 
cost-savings of almost $9,000 per White patient associated with PCC and directional (yet not 
statistically significant) savings among African Americans with PCC, suggesting PCC is a cost-
effective intervention, but that larger studies across multiple medical centers are needed to 
understand why PCC is not significantly associated with reductions in future costs among African 
Americans. Most notably, Chapter 3 also showed how PCC is associated with dramatic increases 
in hospice use among both African Americans and Whites with PCC. Chapter 3 also provided 
helpful cost and utilization data on underrepresented racial minority populations. Finally, Chapter 
4 revealed risk factor profiles for PCC 0-14 days before death, 15-60 days before death, and 
greater than 60 days before death. Together, these results point to some of the many benefits of 
PCC, including opportunities to discuss and document care goals, enroll in hospice care or 
choose less aggressive treatment, and conserve hospital resources in ways that align with patient 
preferences. The results also suggest PCC may play different roles in acute care utilization 
decision-making among different racial/ethnic groups and that other unmeasured factors may 
contribute to PCC timing and effectiveness, highlighting the need for clinicians to adapt PCC to 
patient and family needs, and for PCC to be integrated in care earlier in the illness experience. 
Major Findings 
Chapter Two: End-of-Life Discussions and Advance Care Planning are Associated with 
Lower EOL Costs and Less Aggressive Healthcare in Persons with Cancer  
High costs near the end-of-life (EOL) represent utilization of costly acute and life-
prolonging care near death5 and are associated with poor quality of death among patients.2 High 
costs burden patients,38-42 families,43 and health systems responsible for providing cost-effective, 
high-quality care.21 Importantly, costly aggressive care does not always align with patient goals 
and preferences.10 As the second leading cause of death worldwide44,45 and one of the most 
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expensive conditions to treat,46 cancer uniquely challenges clinicians to provide evidence-based 
and cost-effective care aligned with patient preferences. Patient-provider discussions about care 
goals and EOL preferences are associated with less aggressive care near death2,20,47,48 and lower 
costs,49,50 making them a useful intervention for enabling health systems to improve concordance 
between care preferences and actual care delivered51 and increasing quality of care48 while 
managing resources.21  
The systematic review found that among patients with advance-stage cancer, 
discussions involving ACP, EOL or GOC were associated with lower acute healthcare costs in the 
last 30 days of life (median $1,048 vs. $23,482; P < .001), but more cost research is needed. The 
review also found these discussions are associated with less utilization of costly acute and 
aggressive care near death and greater use of hospice care, which is associated with lower costs 
and higher quality care. Specifically, the review found EOL and care planning discussions were 
associated with lower likelihoods of acute care [Odds Ratios (OR) ranging 0.43 to 0.69], intensive 
care (ORs ranging 0.26 to 0.68), emergency department use, and chemotherapy near death 
(ORs 0.41, 0.57); shorter hospital length of stay; and greater use of hospice (ORs ranging 1.79 to 
6.88) and odds for death outside the hospital. Furthermore, the review found that the timing of 
these conversations was important. Perhaps because patients and families had more time to 
understand prognosis and consider care options in light of patient values and goals, earlier 
conversations (30 or more days before death) were found to be more strongly associated with 
less aggressive care outcomes than later conversations. 
Based on the review’s findings, clinicians can conclude that EOL and care planning 
discussions are effective at helping patients achieve dying experiences that involve less 
aggressive care, and that these conversations should occur earlier in the care continuum for all 
cancer patients. Per this review, less aggressive care associated with EOL discussions also 
appears to be associated with significant cost savings, which also benefit health systems. 
However, cost data was very limited. More research is needed to understand the ways these 
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discussions are associated with EOL costs and what influences the timing of when patients 
receive these conversations.   
Chapter Three: Palliative Care Consultation is Associated with Lower Costs for White 
Patients and Greater Hospice Utilization for African Americans, Whites, and Other 
Racial/Ethnic Minorities  
Even though race does not predict EOL preferences,52,53 African Americans and other 
racial/ethnic minorities are less likely than Whites to receive hospice care54,55 and more likely to 
prefer and receive costly acute or aggressive care near death24,31-36,56,57  and die in hospitals.31 
These differences in EOL acute care utilization result in significantly greater EOL costs for African 
Americans and other racial/ethnic minorities compared to Whites,31 even after controlling for other 
factors.58 Unfortunately, high EOL costs, which reflect greater utilization of acute and intensive 
care services, are associated with poorer quality of death.2 Goals-of-care and EOL discussions 
with healthcare providers, such as those that occur during PCC, are associated with less 
aggressive EOL treatment2,10,20,21,59-65 that is perceived to be higher quality2,9,37,47 and significantly 
lower acute care costs following discussion, including across hospitalizations.21,22 Unfortunately, 
African Americans and other racial/ethnic minorities are less likely than Whites to have important 
care planning and EOL discussions with their healthcare providers.24-29 Early evidence, however, 
suggests race is not a factor in which patients receive PCC, making it a possible solution for 
helping to overcome racial disparities in EOL care. However, studies assessing associations 
between EOL or GOC discussion, or PCC, and costs have not analyzed cost outcomes by race.  
In this study, the association between PCC and acute care costs across hospitalizations 
following discharge from an admission involving PCC was examined (Aim 2a). This secondary 
analysis of preexisting clinical and administrative data included 35,154 African American and 
White patients with serious illness who were hospitalized at an urban academic medical center. A 
portion of the patients received PCC (African Americans with PCC, N = 383; Whites with PCC, N 
= 814). Variables of age, gender, Medicaid status, primary diagnosis, All-patient refined diagnosis 
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related group (APR-DRG) Risk of Mortality, APR-DRG Severity of Illness, intensive care unit 
(ICU) care during index admission, ICU care greater than six days during index admission, 
Oncology services during index admission, acute care costs accumulated during the index 
admission to represent acute care utilization, acute care hospitalization in 30 days prior to index 
admission were used to match patients who received PCC and patients who didn’t receive PCC 
for both racial groups, resulting in two separate race-based stratified propensity score models. 
For each model, patient data from the two propensity groups most likely to have received PCC 
were used to assess outcomes. 
Stratified propensity score modeling for African American patients found African 
Americans who received PCC were less likely to incur “any future acute care cost” compared to 
African Americans who did not receive PCC (31.9% vs. 37.7%, P = 0.047), but differences in total 
future acute care costs were not statistically significant ($11,651 vs. $15,050, P = 0.09). Of great 
importance, African Americans with PCC were more likely to be discharged to hospice from index 
admission (36.5% vs. 2.4%, P < 0.0001), suggesting PCC is effective at increasing quality 
outcomes for African Americans near death. Significant differences in 30-day readmissions, 
future hospital days, future ICU admission or number ICU days were not found.  
Stratified propensity score modeling for White patients found Whites who received PCC 
were less likely to incur “any future acute care cost” compared to Whites who did not receive PCC 
(25.9% vs. 35.5%, P < 0.0001) with a significant difference in mean accumulated future acute 
care costs ($8,095 vs. $16,799, P < 0.001), representing an average cost-savings of $8,704 per 
patient. Whites with PCC were more likely to be discharged to hospice from index admission 
(42.7% vs. 3.0%, P < 0.0001); had lower 30-day readmissions (10.2% vs. 16.7%, P < 0.0001); 
and had fewer future days spent hospitalized (3.7 vs. 6.3 days, P < 0.0001).  
In the secondary aim of this study (Aim 2b), which included an additional 2,946 patients 
from the same parent dataset, Asians (PCC, N = 48; No-PCC, N = 913), Hispanics (PCC, N = 22; 
No-PCC, N = 829), and patients who self-reported as other racial/ethnic minorities (including 
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American Indians/Alaskan Natives, Native Hawaiians/Pacific Islanders, and “Other” race/ethnicity) 
(PCC, N = 39; No-PCC, N = 1,095) were described in terms of index admission acute care and 
intensive care utilization, discharge to hospice, DNR documentation, and future healthcare 
utilization and costs following discharge from index admission. These patient groups were not 
matched using propensity score modeling, so their results are not comparable to the outcomes of 
the propensity-matched African American and White cohort. Descriptive statistics found that PCC 
is associated with increased hospice use for Asians, Hispanics, and patients who self-report as 
“Other” race/ethnicity (including Native Americans and Pacific Islanders). Finally, when patients 
who had received PCC were compared by race/ethnicity, no significant racial/ethnic differences in 
discharge to hospice were found, suggesting PCC is effective at supporting quality EOL care 
across racial/ethnic groups.  
Chapter Four: Palliative Care Consultation is Needed Earlier Across Patient Populations, 
Especially ICU Patients and Hispanic and “Other” Racial/Ethnic Minority Patients  
To understand prognosis and consider care options in light of personal values and 
preferences, patients with serious illness need time to discuss their health and goals with 
providers. If discussions about care planning or EOL occur too close to death, patients may make 
pressured decisions, or fail to communicate desires or decisions, leading to care that does not 
align with their preferences.20,66,67 Care planning and EOL discussions are associated with higher 
quality EOL care,7,13 evidenced by associations with less aggressive treatment and lower use of 
intensive care,2,13,17,19-21 lower hospitalization and 30-day readmission rates,2,19,21,62 greater use of 
hospice and fewer in-hospital deaths.2,13,16,20,21,68 In addition, the timing of these conversations 
matters: evidence suggests each additional day from hospital admission to discussion is 
associated with increased risk of aggressive treatments and in-hospital death, and greater odds a 
patient will receive ICU care.13 There are many benefits to early PCC69-71 and GOC48,72 
conversations, yet patients often have these conversations close to death or not at all.18,73 
Understanding which patients are at risk for late conversations may help clinicians initiate these 
important discussions earlier, which may contribute to improved quality EOL care.48 
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In this study, risk factor profiles were developed to better understand the interaction of 
variables associated with the timing of palliative care consultations involving PCC 0-14 days 
before death (“PCC close to death”), 15-60 days before death (“moderately-timed PCC”), and 
greater than 60 days before death (“early PCC”) among patients who received PCC at an 
academic medical center in the Northeast region. A sample of 1,141 patients who received PCC 
prior to death were assessed in this secondary analysis of pre-existing clinical and administrative 
data. De-identified patient data from a study about cost-savings associated with PCC across 
hospital admissions21 was supplemented with new data that identified Medicaid status and the 
number of days between first inpatient PCC and patient death. First, an adjusted multinomial 
logistic regression model was created to identify variables associated with the timing of PCC 
before death. These variables were intended to inform creation of a classification and regression 
tree (CART) model. A CART analysis was applied to understand how independent variables 
available in the dataset interacted to create patient profiles associated with the timing of PCC 
before death.  
Variance Inflation Factor was less than three for all variables in the study, indicating no 
evidence of multicollinearity among variables. Adjusted multinomial logistic regression did not find 
evidence of any significant associations among variables with PCC timing, suggesting other 
unmeasured factors are associated with timing and that patients of all types are at risk for 
consultations close to death. Small sample sizes within groups, which diminished in the context of 
variable sub-categorization, may also have contributed to this finding. However, differences were 
identified at the 0.05 significance level between moderately-timed PCC when compared to early 
PCC, and between PCC close to death when compared to early PCC. Compared to referrals from 
Oncology specialists, for example, patients referred to PCC by General Medicine/Hospitalists 
were two times more likely to have consults close to death than early (OR = 2.02, 95% 
Confidence Interval 1.16, 3.53; P = 0.01), with no significant difference for moderately-timed PCC 
compared to early. Compared to patients over age 75, patients aged 56-60 were almost two 
times more likely to have consults close to death than early (OR = 1.94, 95% Confidence Interval 
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1.09, 3.47; P = 0.03), with no significant difference for moderately-timed PCC relative to early. 
And compared to patients with cancer, patients in the “Other” diagnosis category (e.g., skin 
conditions, psychiatric conditions, traumatic injuries, procedural complications) were less likely to 
receive a moderately-timed consult than early consult (OR = 0.47, 95% Confidence Interval 0.22, 
0.10; P = 0.049) and, although not significant, less likely to have PCC close to death (OR = 0.53, 
95% Confidence Interval 0.28, 1.01; P = 0.052) compared to early. Conditions were included in 
the “Other” category if they did not fit into one of the other larger diagnosis categories of the study 
or had smaller sample sizes.  
The CART model effectively identified which patients received PCC 0-14 days before 
death (88.2% sensitivity), but not which patients received PCC 15-60 days before death (27.4% 
sensitivity) or PCC greater than 60 days before death (1.7% sensitivity). The model showed high 
specificity for early (99.1%) and moderately-timed (82.1%) PCC, suggesting the model was 
effective at identifying which patients did not receive early or moderately-timed PCC. This finding 
is significant because early and moderately-timed PCC are generally considered better for 
patients and are associated with more optimal outcomes than PCC close to death. These results 
suggest the model can be used to help clinicians identify which patients are not having early or 
moderately-timed PCC, enabling clinicians to better target these patients and develop 
interventions that provide more timely consultations. 
The CART model showed 64% of patients with extreme severity of illness received PCC 
close to death. ICU use during index admission was also associated with high probability of PCC 
close to death. For example, ICU patients with extreme illness severity were more likely to 
receive PCC close to death (67%). Half of ICU patients with less than extreme severity of illness 
also received PCC within 14 days of death (50%), a probability that was lower than the overall 
sample but still incredibly high. Patients with extreme illness severity who were in the ICU and 
were Hispanic, “Other” racial/ethnic minority (American Indian/Alaskan Native, Native 
Hawaiian/Pacific Islander, or “Other” race/ethnicity), or did not disclose their race/ethnicity were 
even more likely to receive PCC close to death (85%). Being younger (age less than 46) or older 
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than 75 further increased the probability among such patients (98%). Non-ICU patients with 
extreme severity of illness and most conditions (excluding heart failure, respiratory disorders, or 
“Other” disorders) who were not admitted to the hospital 30 days prior, age <40 and >75 also had 
very high probability of PCC close to death (96%).  
On the other hand, patients with non-extreme illness severity who were not in the ICU 
were less likely to receive PCC close to death (24%). Patients with extreme severity of illness 
who did not have ICU care but had heart failure, a respiratory disorder, or “Other” disorder had 
only 17% probability of PCC close to death (and 80% probability of early PCC). Non-ICU patients 
with extreme illness severity with conditions other than heart failure, respiratory disorder, or 
“Other” condition who did not receive Oncology care during index admission but had been 
admitted to the hospital 30 days prior also demonstrated low probability for PCC close to death 
(19%). Finally, patients with extreme severity of illness who did not receive ICU care during index 
admission demonstrated varying probability for PCC timing (48% for 0-14 days, 31% for 15-60 
days, 21% for > 60 days). It is unknown if other factors contributed or if this is a case of reverse 
causation.  
The secondary, descriptive aim of this study revealed many findings. First, the data 
showed that, despite having significantly more days to use acute care services and accrue costs 
before death, patients with PCC more than 60 days before death had only $8,993 greater median 
acute care EOL costs than patients who had PCC within 14 days of death. Research is needed to 
understand the per day difference in costs associated with each additional day PCC occurred 
before death. As patients neared death, they seemed to become more likely to change their care 
goals during PCC (50% early PCC, 76% moderately-timed PCC, 93% PCC close to death; P 
<0.0001). Similarly, the presence of a DNR increased the closer a patient was to death (26% 
early PCC, 59% moderately-timed PCC, 86% PCC close to death; P < 0.0001).   Finally, patients 
were discharged to hospice from a hospitalization involving PCC when PCC occurred closer to 
death (10% early PCC, 33% moderately-timed PCC, 31% PCC close to death; P < 0.0001), 
suggesting patients farther from death may not be ready to immediately enroll in hospice. These 
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figures do not describe hospice enrollment occurring after discharge from a PCC hospitalization. 
Patients who receive PCC may choose to later enroll in hospice after considering their goals and 
care options. Earlier PCC gives patients and families more time to consider hospice and, if 
desired, benefit from its high-quality care longer. 
Limitations 
Systematic review (Chapter 2) 
The systematic review presented in Chapter 2 had multiple limitations.  First, only one 
study tested causal relationships through a randomized controlled trial. This study was also the 
only one to explore associations among EOL discussions for GOC and costs; the other two cost-
related studies used advance directives as a comparator and insufficiently provided cost data. 
Studies in the review did not uniformly define measured variables, uniformly collect measured 
variables, or assess the same utilization variables, making synthesized comparisons difficult and 
meta-analysis not possible. Studies that used medical records to identify EOL discussions could 
not account for undocumented conversations and studies that used self-report to measure 
discussions could not account for recall bias. In addition, studies featured patients with different 
types of cancer in health systems that have varying levels of training, EOL intensive care 
utilization, and resources. Although these differences may limit generalizability and the ability to 
synthesize results, the review provided important clinical insights that may help improve EOL care 
for persons with cancer while further justifying investment in interventions that improve EOL 
communication. 
Secondary analysis of patient data from a retrospective cohort study (Chapters 3 and 4) 
The studies in Chapters 3 and 4 also featured limitations. The analyses included patient 
data from a single, urban academic medical center served by a well-established palliative care 
team. The medical center and its resources, clinicians, and patient population may not represent 
all hospitals, limiting the generalizability of results. Furthermore, what was measured in each of 
the studies was limited to variables available in the dataset and medical record system. We were 
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unable to measure other variables of interest because they were either not available in the 
medical record system or in the pre-existing dataset. In the propensity-score matching study 
(Chapter 3) we were unable to control for unknown or unmeasured confounding variables such as 
comorbidities, income, insurance status, education level, health literacy, religious beliefs, or 
duration of survival. In the absence of diagnostic tests, we were also unable to understand how 
closely propensity groups matched across each of the ten variables. This is a common limitation 
in propensity score matching studies when groups, such as the race-based PCC groups, are 
limited in size. However, as evidenced by the two highest propensity score tiers’ nearly identical 
minimums and maximums and similar mean propensities, which were used in the analysis, the 
per-race PCC and Non-PCC groups were matched well across variables such that they had 
similar propensity for PCC. Similar propensity for PCC enabled meaningful comparison and 
reliable analysis of results.  
In the PCC timing study (Chapter 4), we were unable to test for interactions and 
associations among timing and variables such as health literacy, education, religiosity, immigrant 
status, language fluency, expected duration of survival, frailty, outpatient GOC discussions, family 
dynamics, and more. Unmeasured variables may have been distributed differently in patients who 
received PCC and those who did not (Chapter 3) and may have been more strongly associated 
with PCC timing or contributed to risk factor profiles more strongly associated with PCC timing 
(Chapter 4). 
 Next, the analyses could only measure variables tracked within the health system and 
available in the dataset. The index PCC may have occurred before some of the correlates, such 
as ICU admission, which makes conclusions about chronology or prediction unfeasible. In 
addition, the analyses could not measure acute care utilization or costs incurred in community 
hospitals outside the health system or care received in skilled nursing, outpatient settings, or in 
the home. For hospice use, the analyses were unable to assess hospice use following discharge 
from the index admission, which may have occurred. Chapter 4 was unable to include deceased 
patients whose death information was not in the health system’s records. These patients may 
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have differed from patients included in the analysis; measured variables may have been 
distributed differently across the three groups, resulting in different associations with PCC timing.   
Despite these limitations, study results are timely and useful. Results of Chapter 3 may 
be used to show cost and utilization outcomes, including hospice use, associated with PCC 
beyond the initial hospitalization among African Americans and among Whites in a sample 
matched on known covariates within racial groups.21,61,63 Results of Chapter 4 may be used to 
increase understanding of risk factor profiles associated with PCC close to death to support 
clinicians in better providing more timely GOC and EOL discussions among seriously ill persons. 
Directions for Future Work 
The results of this dissertation research contribute to a growing body of literature that 
identifies the cost-effectiveness and clinical-effectiveness of palliative care consultation and 
supports its delivery across racial/ethnic patient populations early in the illness trajectory. The 
results underscore a need for more cost research on PCC and EOL communication to enable 
hospital administrators to support the development and expansion of palliative care programs. To 
reduce prevalence of PCC close to death, as demonstrated in our study, PCC should be scaled in 
primary, community settings where PCC can be integrated into care earlier. Furthermore, to avoid 
racial/ethnic disparities in risk of receiving PCC close to death, PCC should be expanded in 
settings with racially/ethnically diverse patient populations. Study results generate new questions 
and underscore the need for research that explains findings and measures variables not available 
in the parent study dataset.  
An important area for future research involves racial/ethnic differences in EOL 
communication and outcomes. Specifically, research is needed to understand why our study 
found PCC was associated with an increase in hospice use but not a statistically significant 
reduction in future acute care costs among African Americans. From a cost and utilization 
perspective, research is needed to understand if there are (a) racial differences in readmission 
rates or acute care use among PCC and Non-PCC hospice patients following discharge, (b) racial 
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differences in non-hospice patient acute care utilization, specifically the types of care and 
frequency of care, following discharge, and (c) profiles of patients who incur the greatest future 
acute care costs and utilization. In terms of PCC delivery, research is needed to understand or 
explain possible disparities in the effectiveness of PCC among racial groups. Specifically, 
research is needed to identify factors not measured in this study that may contribute to PCC 
differences among racial groups, such as patient-provider racial/ethnic concordance, patient-
provider language concordance, education, income, religiosity and its role in decision-making, 
health literacy and prognosis comprehension, documented or undocumented immigrant status, 
family and cultural dynamics’ influence on decision-making, and the number of PCC visits over 
time both inpatient and in the community. 
In addition, research is needed to understand which aspects of communication or types 
of PCC discussion content influenced patient decision-making, whether content differed by 
race/ethnicity, and if differences in content were associated with utilization outcome differences. 
For patient groups with historically lower rates of hospice use or higher rates of aggressive care 
near EOL, such research may be useful. It would also be helpful to understand how patients who 
intentionally choose aggressive EOL care differ from patients who receive aggressive care by 
default or for other reasons, such as family dynamics or low health literacy. 
Due to small sample sizes, the findings for Asians, Hispanics, and “Other” racial/ethnic 
minorities in Chapter 3 are hypothesis-generating. Research with adequately large sample sizes 
of racial/ethnic minorities, particularly Asians and Hispanics, is needed to better understand PCC 
associations with outcomes in such understudied populations. It is especially important that future 
research include measures of language, immigration status, education, and cultural values such 
as the role of family in decision-making, as these variables were lacking in this dissertation study 
and may have influenced preliminary results. In addition, specific questions emerged from the 
study that are worth further exploration. For example, what factors explain why Asians with PCC 
were found to have the lowest median index admission costs and the highest mean index 
admission costs among PCC patients across racial groups? What makes utilization vary so 
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dramatically in that population and can PCC interventions better address Asian patient and family 
needs? 
Finally, the results of these studies should be replicated in other populations and health 
settings, including community settings where earlier PCC is more likely to occur when available. 
The PCC timing study should be replicated in larger, more diverse samples with more relevant 
variables to better identify risk factor profiles for patients not only likely to receive PCC close to 
death, but also patients likely to receive moderately-timed and early PCC. In addition, primary 
studies designed to account for all known confounders are needed. Understanding how patients 
experience PCC earlier in the care continuum and how earlier community-based PCC is 
associated with EOL care quality and cost outcomes would help clinicians and policy makers 
better understand the utility of these discussions in community settings. 
Research Implications 
Palliative care consultation was found to be a powerful intervention for increasing hospice 
use and decreasing the presence of “any” future acute care costs (representing any future acute 
care utilization) among African Americans. Even stronger outcomes were found among Whites 
who had PCC. As such, development in PCC should be supported in inpatient settings, as 
studied in this dissertation, and in the community through primary palliative care, where PCC can 
be initiated earlier in the care continuum. Innovative workforce solutions and interdisciplinary care 
models featuring nurse leadership are needed to better provide PCC to patients with serious 
illness in community settings. To enable interdisciplinary and nurse-led delivery of primary 
palliative care, workforce training, novel payment methods, and supportive public policies are 
needed. In addition, our results highlight a critical need for a systematic process to engage ICU 
patients in PCC. Nurses can and should play an important role in the implementation of PCC 
across settings. 
Finally, the results of this research should encourage nurses and physicians across care 
settings to initiate GOC conversations earlier with patients across racial/ethnic groups and take 
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into account a patient’s language, cultural preferences, and health literacy. Awareness of risk 
factor profiles associated with PCC close to death should prompt providers to target patients at 
risk for late conversations. In addition, results from this dissertation can be used to help design 
interventions that target patients at risk for not receiving early or moderately-timed PCC.  
Ethical Considerations 
Findings from this dissertation should be considered in light of clinical ethics and policies 
that promote ethical care for patients with serious illness. All humans eventually die and yet the 
modern American acute care health system is designed to maintain physical life and delay the 
natural course of death, sometimes indefinitely, for people with serious illness who are at high risk 
of dying.13 The quality of life that accompanies such life-extending care may not align with patient 
goals, values, or wishes, which is why it is so important that healthcare providers have open, 
ongoing discussions with patients and families starting early in the illness experience about what 
quality of life and quality of death mean to the patient.74 While it is a clinician’s responsibility to 
explain the implications and consequences of any given treatment or type of care, patients are 
autonomous and must be free to make well-informed decisions that align with their own desires 
and sense of well-being.75  
Health literacy and other social determinants of health affect the choices people make 
and the quality care they receive near death. Research is needed to not only understand 
disparities in care stemming from social determinants of health, but also address and overcome 
these differences and the systematic issues that may enable them. Further research is also 
needed to design and implement innovative care models, workforce solutions, payment models, 
and policies to deliver palliative care earlier and in community settings, and to better meet patient 
needs across the care continuum. Better meeting patient and family needs across the illness 
experience, and not primarily during inpatient hospitalization when payment schemes allow for 
delivery of palliative care, is an ethical priority. 
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Finally, although this dissertation found PCC was associated with cost reductions in 
some populations, reducing costs should not be a major reason for engaging patients in PCC or 
GOC discussions. Instead, clinicians and payers should focus on how PCC increases patient 
autonomy, improves quality of care—and as this dissertation showed, increases hospice use 
across all racial/ethnic patient populations—and saves resources.50 Better communication can 
result in better quality EOL care, with lower costs naturally following, benefiting patients and 
systems alike.19 
Conclusion 
This three-part dissertation increased knowledge of palliative care consultation 
associations with acute care costs across hospitalizations and use of hospice services among 
African American, White, and other patients with serious illness, explored risk factor profiles 
associated with the timing of PCC before death, and described aspects of a hospitalization 
involving PCC such as changes in goals-of-care plans and DNR documentation, and how these 
elements differed based on PCC timing. The systematic review showed EOL discussions with 
advanced cancer patients are associated with a median $22,434 reduction in costs in the last 30 
days of life and lower odds of acute care at EOL, intensive care at EOL, chemotherapy near 
death, emergency department use and shorter hospital length of stay, greater use of hospice, and 
greater odds of patient death outside a hospital. The review found stronger results in discussions 
occurring more than 30 days before death compared to later discussions. The review also 
revealed a major need for more cost research related to EOL discussions and research about the 
timing of such discussions.  
The secondary analysis in Chapter 3 sought to help fill that research gap by comparing 
cost-savings associated with PCC in a propensity score-matched study of African American and 
White patients with serious illness with and without PCC. The study found PCC was associated 
with an average reduction of $8,704 in future acute care costs among White patients, but cost 
differences were not significant among African Americans. The presence of any future acute care  
 
 
 
167 
150 
cost, representing any acute care utilization following a hospitalization with PCC, was significantly 
lower in African Americans and Whites with PCC. Most importantly, PCC was found to be 
associated with significantly higher hospice use among Whites, African Americans, Hispanics, 
Asians, and patients who self-identify as “Other” race/ethnicity. More research is needed to 
understand why cost reductions were significant in White populations but not African Americans. 
The secondary analysis in Chapter 4 further contributed to the growing field of palliative care and 
EOL communications research by identifying risk factor profiles associated with the timing of PCC 
before death. The model was most effective at identifying patients likely to receive PCC close to 
death (0-14 days before death), making it a useful tool for clinicians seeking to provide timely 
GOC discussions and PCC to patients at-risk for late consultation.  
This dissertation research recognizes ethical issues related to assessing costs and EOL 
patient care and supports each patient’s autonomy and right to make informed decisions about 
care. The findings of this body of work can be used to improve patient-provider communication 
about GOC and EOL, possibly improving the quality of EOL care patients receive or concordance 
between patient wishes and actual care received. The results help justify investment in palliative 
care in hospitals and in the community and can be used to enable the development of novel 
models of palliative care delivery and payment schemes to better meet patient needs throughout 
the illness experience. 
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d 
w
er
e 
st
ra
tif
ie
d 
ac
co
rd
in
g 
to
 a
 b
in
ar
y 
va
ria
bl
e 
of
 
"P
C
C
 fo
r G
O
C
” a
nd
 “N
o 
PC
C
 fo
r G
O
C
” b
as
ed
 o
n 
da
ta
 a
va
ila
bl
e 
in
 th
e 
pa
llia
tiv
e 
ca
re
 re
gi
st
ry
 1 .
 T
he
 fi
rs
t P
C
C
 fo
r G
O
C
/E
O
L 
du
rin
g 
th
e 
st
ud
y 
pe
rio
d 
is
 d
ef
in
ed
 a
s 
th
e 
pa
tie
nt
’s
 in
de
x 
ad
m
is
si
on
, r
ef
er
re
d 
to
 a
s 
in
de
x 
ad
m
is
si
on
 o
r i
nd
ex
 h
os
pi
ta
liz
at
io
n.
 
D
ic
ho
to
m
ou
s,
  
C
at
eg
or
ic
al
 
PC
C
 0
-1
4 
da
ys
 b
ef
or
e 
de
at
h 
In
pa
tie
nt
 P
C
C
 to
 d
is
cu
ss
 G
O
C
/E
O
L 
oc
cu
rri
ng
 0
-1
4 
da
ys
 b
ef
or
e 
pa
tie
nt
 
de
at
h,
 a
s 
re
co
rd
ed
 in
 h
ea
lth
 s
ys
te
m
 e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s 
an
d 
th
e 
pa
llia
tiv
e 
ca
re
 re
gi
st
ry
. 
D
ic
ho
to
m
ou
s,
  
C
at
eg
or
ic
al
 
PC
C
 1
5-
60
 d
ay
s 
be
fo
re
 
de
at
h 
In
pa
tie
nt
 P
C
C
 to
 d
is
cu
ss
 G
O
C
/E
O
L 
oc
cu
rri
ng
 1
5-
60
 d
ay
s 
be
fo
re
 p
at
ie
nt
 
de
at
h,
 a
s 
re
co
rd
ed
 in
 h
ea
lth
 s
ys
te
m
 e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s 
an
d 
th
e 
pa
llia
tiv
e 
ca
re
 re
gi
st
ry
. 
D
ic
ho
to
m
ou
s,
  
C
at
eg
or
ic
al
 
PC
C
 >
 6
0 
da
ys
 b
ef
or
e 
de
at
h 
In
pa
tie
nt
 P
C
C
 to
 d
is
cu
ss
 G
O
C
/E
O
L 
oc
cu
rri
ng
 6
1+
 d
ay
s 
be
fo
re
 p
at
ie
nt
 
de
at
h,
 a
s 
re
co
rd
ed
 in
 h
ea
lth
 s
ys
te
m
 e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s 
an
d 
th
e 
pa
llia
tiv
e 
ca
re
 re
gi
st
ry
. 
D
ic
ho
to
m
ou
s,
  
C
at
eg
or
ic
al
 
Fu
tu
re
 a
cu
te
 c
ar
e 
co
st
s 
(d
ol
la
rs
) (
di
re
ct
 c
os
ts
) 
“F
ut
ur
e 
ac
ut
e 
ca
re
 c
os
ts
” i
s 
ca
lc
ul
at
ed
 b
y 
ad
di
ng
 to
ge
th
er
 th
e 
di
re
ct
 c
os
ts
 
fro
m
 a
ll 
ho
sp
ita
liz
at
io
ns
 a
fte
r t
he
 in
de
x 
ho
sp
ita
liz
at
io
n 
du
rin
g 
th
e 
st
ud
y 
pe
rio
d.
 C
os
t i
nc
ur
re
d 
du
rin
g 
th
e 
in
de
x 
ho
sp
ita
liz
at
io
n 
ar
e 
ex
cl
ud
ed
. D
ire
ct
 
co
st
s 
re
pr
es
en
t t
he
 b
es
t e
st
im
at
e 
of
 th
e 
ac
tu
al
 c
os
t o
f p
ro
vi
di
ng
 h
os
pi
ta
l 
se
rv
ic
es
 in
cl
ud
in
g 
nu
rs
in
g 
la
bo
r, 
ot
he
r a
llie
d 
he
al
th
 p
ro
fe
ss
io
na
l l
ab
or
, 
ph
ar
m
ac
eu
tic
al
s,
 s
up
pl
ie
s,
 p
ro
ce
du
re
s,
 te
st
in
g,
 a
nd
 e
m
er
ge
nc
y 
de
pa
rtm
en
t (
ED
) v
is
its
 th
at
 re
su
lte
d 
in
 h
os
pi
ta
liz
at
io
n.
 In
di
re
ct
 c
os
ts
 (i
.e
., 
ov
er
he
ad
 c
os
ts
 s
uc
h 
as
 m
ed
ic
al
 re
co
rd
s,
 p
at
ie
nt
 fi
na
nc
ia
l a
cc
ou
nt
in
g,
 
de
pr
ec
ia
tio
n 
of
 fa
ci
lit
ie
s,
 a
nd
 th
e 
co
st
 o
f u
til
iti
es
) a
re
 n
ot
 in
cl
ud
ed
 b
ec
au
se
 
C
on
tin
uo
us
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Va
ria
bl
e 
D
es
cr
ip
tio
n 
Ty
pe
 o
f d
at
a 
th
ey
 a
re
 fi
xe
d 
in
de
pe
nd
en
t o
f p
at
ie
nt
 v
ol
um
e 
an
d 
ca
nn
ot
 b
e 
sa
ve
d 
by
 
av
oi
di
ng
 re
ad
m
is
si
on
s 
to
 th
e 
ho
sp
ita
l. 
“F
ut
ur
e 
ac
ut
e 
ca
re
 c
os
ts
” w
er
e 
ob
ta
in
ed
 fr
om
 M
cK
es
so
n 
H
ea
lth
 S
ol
ut
io
ns
 (K
in
g 
of
 P
ru
ss
ia
, P
A)
, t
he
 
he
al
th
 s
ys
te
m
’s
 c
os
t a
cc
ou
nt
in
g 
sy
st
em
. T
hi
s 
sy
st
em
 tr
ac
ks
 th
e 
ch
ar
ge
s 
co
de
d 
du
rin
g 
ea
ch
 h
os
pi
ta
l e
nc
ou
nt
er
. 
 Th
is
 v
ar
ia
bl
e 
is
 a
ls
o 
us
ed
 to
 c
al
cu
la
te
 E
O
L 
ac
ut
e 
ca
re
 c
os
ts
 fo
llo
w
in
g 
PC
C
, a
s 
co
st
s 
ar
e 
tra
ck
ed
 fo
rw
ar
d 
to
 th
e 
po
in
t o
f d
ea
th
. 
 
Fu
tu
re
 a
cu
te
 c
ar
e 
– 
an
y 
co
st
 (y
es
, n
o)
 
If 
a 
pa
tie
nt
 w
as
 b
ille
d 
fo
r a
ny
 a
cu
te
 c
ar
e 
se
rv
ic
e,
 re
su
lti
ng
 in
 a
ny
 a
cu
te
 
ca
re
 b
illa
bl
e 
ch
ar
ge
 a
cc
or
di
ng
 to
 M
cK
es
so
n 
H
ea
lth
 S
ys
te
m
s 
fin
an
ci
al
 c
os
t 
ac
co
un
tin
g 
sy
st
em
 fo
llo
w
in
g 
di
sc
ha
rg
e 
fro
m
 th
e 
in
de
x 
ho
sp
ita
l a
dm
is
si
on
, 
as
 re
co
rd
ed
 in
 h
ea
lth
 s
ys
te
m
 e
le
ct
ro
ni
c 
re
co
rd
s.
  
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
 
EO
L 
ac
ut
e 
ca
re
 c
os
ts
 (d
ire
ct
 
co
st
s)
 
To
ta
l d
ire
ct
 a
cu
te
 c
ar
e 
co
st
s 
fro
m
 a
ll 
ho
sp
ita
liz
at
io
ns
 a
fte
r d
is
ch
ar
ge
 fr
om
 
th
e 
in
de
x 
ho
sp
ita
liz
at
io
n 
in
 w
hi
ch
 th
e 
in
iti
al
 P
C
C
 o
cc
ur
re
d 
du
rin
g 
th
e 
st
ud
y 
pe
rio
d,
 to
 th
e 
po
in
t o
f p
at
ie
nt
 d
ea
th
, a
s 
tra
ck
ed
 b
y 
ho
sp
ita
l c
os
t a
cc
ou
nt
in
g 
so
ftw
ar
e 
(M
cK
es
so
n 
H
ea
lth
 S
ys
te
m
s,
 K
in
g 
of
 P
ru
ss
ia
, P
A)
. D
ire
ct
 c
os
ts
 
pr
ov
id
e 
th
e 
be
st
 in
di
ca
tio
n 
of
 th
e 
ac
tu
al
 c
os
t o
f h
os
pi
ta
l s
er
vi
ce
s 
in
cl
ud
in
g 
nu
rs
in
g 
la
bo
r, 
ot
he
r a
llie
d 
he
al
th
 p
ro
fe
ss
io
na
l l
ab
or
, p
ha
rm
ac
eu
tic
al
s,
 
su
pp
lie
s,
 p
ro
ce
du
re
s,
 a
nd
 te
st
in
g.
 In
di
re
ct
 c
os
ts
 (i
.e
., 
ov
er
he
ad
 c
os
ts
 s
uc
h 
as
 m
ed
ic
al
 re
co
rd
s,
 p
at
ie
nt
 fi
na
nc
ia
l a
cc
ou
nt
in
g,
 d
ep
re
ci
at
io
n 
of
 fa
ci
lit
ie
s,
 
an
d 
th
e 
co
st
 o
f u
til
iti
es
) a
re
 n
ot
 in
cl
ud
ed
 b
ec
au
se
 th
ey
 a
re
 fi
xe
d 
in
de
pe
nd
en
t o
f p
at
ie
nt
 v
ol
um
e 
an
d 
ca
nn
ot
 b
e 
re
du
ce
d 
by
 a
vo
id
in
g 
re
ad
m
is
si
on
s 
to
 th
e 
ho
sp
ita
l. 
C
on
tin
uo
us
 
Fu
tu
re
 n
um
be
r o
f d
ay
s 
in
 
th
e 
ho
sp
ita
l (
af
te
r d
is
ch
ar
ge
 
fro
m
 in
de
x 
ad
m
is
si
on
) 
Th
e 
nu
m
be
r o
f d
ay
s 
a 
pa
tie
nt
 w
as
 in
 th
e 
ho
sp
ita
l f
ol
lo
w
in
g 
di
sc
ha
rg
e 
fro
m
 
th
e 
in
de
x 
ad
m
is
si
on
 d
ur
in
g 
th
e 
st
ud
y 
pe
rio
d;
 o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l 
el
ec
tro
ni
c 
m
ed
ic
al
 re
co
rd
s.
 
C
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uo
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D
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cr
ip
tio
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Ty
pe
 o
f d
at
a 
Fu
tu
re
 n
um
be
r o
f d
ay
s 
in
 
IC
U
 (a
fte
r d
is
ch
ar
ge
 fr
om
 
in
de
x 
ad
m
is
si
on
) 
Th
e 
nu
m
be
r o
f d
ay
s 
a 
pa
tie
nt
 w
as
 in
 th
e 
IC
U
 fo
llo
w
in
g 
di
sc
ha
rg
e 
fro
m
 th
e 
in
de
x 
ad
m
is
si
on
 d
ur
in
g 
th
e 
st
ud
y 
pe
rio
d;
 o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l m
ed
ic
al
 
el
ec
tro
ni
c 
re
co
rd
s.
 
C
on
tin
uo
us
 
30
-d
ay
 re
ad
m
is
si
on
s 
(a
fte
r 
di
sc
ha
rg
e 
fro
m
 in
de
x 
ad
m
is
si
on
) 
R
ea
dm
is
si
on
/h
os
pi
ta
liz
at
io
n 
w
ith
in
 3
0 
da
ys
 o
f d
is
ch
ar
ge
 fr
om
 in
de
x 
ho
sp
ita
liz
at
io
n 
(y
es
, n
o)
; o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s.
 
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
 
D
is
ch
ar
ge
 to
 h
os
pi
ce
 (f
ro
m
 
in
de
x 
ad
m
is
si
on
) 
Pa
tie
nt
 w
as
 d
is
ch
ar
ge
d 
to
 h
os
pi
ce
 a
t t
he
 e
nd
 o
f t
he
 in
de
x 
ad
m
is
si
on
 (y
es
, 
no
); 
ob
ta
in
ed
 fr
om
 h
os
pi
ta
l e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s.
 
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
 
Ag
e 
N
um
be
r o
f y
ea
rs
 a
 p
at
ie
nt
 h
as
 li
ve
d 
at
 th
e 
tim
e 
of
 in
de
x 
ad
m
is
si
on
 
di
sc
ha
rg
e,
 c
at
eg
or
iz
ed
 in
 fi
ve
-y
ea
r i
nc
re
m
en
ts
 s
ta
rti
ng
 a
t a
ge
 4
0.
 T
w
o 
ad
di
tio
na
l c
at
eg
or
ie
s—
“u
nd
er
 a
ge
 4
0”
 a
nd
 “o
ve
r a
ge
 9
0”
 w
ill 
be
 in
cl
ud
ed
. 
O
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s.
 
O
rd
in
al
, c
at
eg
or
ic
al
 
G
en
de
r 
M
al
e 
or
 fe
m
al
e 
ge
nd
er
; o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s.
 
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
 
R
ac
e/
et
hn
ic
ity
 
Pa
tie
nt
 s
el
f-r
ep
or
t o
f b
ei
ng
 H
is
pa
ni
c 
or
 n
on
-H
is
pa
ni
c,
 w
hi
te
/C
au
ca
si
an
, 
Bl
ac
k/
Af
ric
an
-A
m
er
ic
an
, A
si
an
, o
r o
th
er
 e
th
ni
ci
ty
. 
N
om
in
al
, c
at
eg
or
ic
al
 
R
ac
e/
et
hn
ic
ity
: W
hi
te
 
Pa
tie
nt
 s
el
f-r
ep
or
t o
f b
ei
ng
 e
xc
lu
si
ve
ly
 w
hi
te
 o
r C
au
ca
si
an
, a
cc
or
di
ng
 to
 
m
ed
ic
al
 re
co
rd
s.
 
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
 
R
ac
e/
et
hn
ic
ity
: A
fri
ca
n 
Am
er
ic
an
 
Pa
tie
nt
 s
el
f-r
ep
or
t o
f b
ei
ng
 B
la
ck
/A
fri
ca
n 
Am
er
ic
an
, a
cc
or
di
ng
 to
 m
ed
ic
al
 
re
co
rd
s.
 
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
 
R
ac
e/
et
hn
ic
ity
: N
on
w
hi
te
 
Pa
tie
nt
 s
el
f-r
ep
or
t o
f b
ei
ng
 B
la
ck
/A
fri
ca
n 
Am
er
ic
an
, H
is
pa
ni
c,
 A
si
an
, 
Am
er
ic
an
 In
di
an
/A
la
sk
an
 N
at
iv
e,
 N
at
iv
e 
H
aw
ai
ia
n/
Pa
ci
fic
 Is
la
nd
er
, M
ix
ed
 
ra
ce
/e
th
ni
ci
ty
, o
r o
th
er
; o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s.
 
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
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Va
ria
bl
e 
D
es
cr
ip
tio
n 
Ty
pe
 o
f d
at
a 
Pr
im
ar
y 
di
ag
no
si
s 
Pr
im
ar
y 
cl
in
ic
al
 d
ia
gn
os
is
 o
f i
lln
es
s 
ba
se
d 
on
 th
e 
di
ag
no
si
s 
re
la
te
d 
gr
ou
p 
(D
R
G
) c
od
ed
 a
t t
he
 ti
m
e 
of
 d
is
ch
ar
ge
. C
at
eg
or
ie
s 
in
cl
ud
e:
 C
ar
di
ov
as
cu
la
r 
di
so
rd
er
, e
nd
oc
rin
e 
di
so
rd
er
, g
yn
ec
ol
og
ic
/u
ro
lo
gi
c 
di
so
rd
er
, s
ol
id
 tu
m
or
 
ca
nc
er
, h
em
at
ol
og
ic
 m
al
ig
na
nc
y,
 n
eu
ro
lo
gi
c 
di
so
rd
er
, p
sy
ch
ia
tri
c 
di
so
rd
er
, 
re
sp
ira
to
ry
 d
is
or
de
r, 
de
m
en
tia
, o
th
er
. T
hi
s 
da
ta
 w
as
 o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l 
m
ed
ic
al
 re
co
rd
s 
an
d 
is
 c
at
eg
or
iz
ed
 b
as
ed
 o
n 
IC
D
-9
 a
nd
 IC
D
-1
0 
co
de
s.
 
N
om
in
al
, c
at
eg
or
ic
al
 
So
ur
ce
 o
f r
ef
er
ra
l t
o 
pa
llia
tiv
e 
ca
re
 
Pr
ov
id
er
 o
r d
ep
ar
tm
en
t w
ho
 re
fe
rre
d 
th
e 
pa
tie
nt
 to
 p
al
lia
tiv
e 
ca
re
, a
s 
re
co
rd
ed
 in
 h
os
pi
ta
l e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s:
 e
m
er
ge
nc
y 
de
pa
rtm
en
t, 
IC
U
, s
pe
ci
al
ty
 p
hy
si
ci
an
. 
N
om
in
al
, c
at
eg
or
ic
al
 
Al
l P
at
ie
nt
 R
ef
in
ed
 
D
ia
gn
os
is
 R
el
at
ed
 G
ro
up
 
(A
PR
-D
R
G
) S
ev
er
ity
 o
f 
Ill
ne
ss
 (S
O
I) 
Th
e 
ex
te
nt
 o
f o
rg
an
 s
ys
te
m
 d
er
an
ge
m
en
t o
r p
hy
si
ol
og
ic
 d
ec
om
pe
ns
at
io
n 
of
 a
 p
at
ie
nt
. S
ev
er
ity
 o
f I
lln
es
s 
is
 m
ea
su
re
d 
in
 fo
ur
 s
ub
ca
te
go
rie
s:
 m
in
or
, 
m
od
er
at
e,
 m
aj
or
, a
nd
 e
xt
re
m
e;
 a
nd
 is
 a
ss
ig
ne
d 
to
 th
e 
pa
tie
nt
 a
t t
he
 ti
m
e 
of
 
di
sc
ha
rg
e 
ba
se
d 
on
 th
e 
pa
tie
nt
’s
 d
ia
gn
os
es
 a
nd
 p
ro
ce
du
re
s 
th
at
 w
er
e 
co
de
d 
fo
r b
illi
ng
 d
ur
in
g 
th
e 
ho
sp
ita
liz
at
io
n.
 S
ev
er
ity
 o
f I
lln
es
s 
is
 m
ea
nt
 to
 
pr
ov
id
e 
a 
ba
si
s 
fo
r e
va
lu
at
in
g 
ho
sp
ita
l r
es
ou
rc
e 
us
e 
or
 to
 e
st
ab
lis
h 
pa
tie
nt
 
ca
re
 g
ui
de
lin
es
. T
he
re
 a
re
 fi
ve
 c
at
eg
or
ie
s:
 m
in
or
, m
od
er
at
e,
 m
aj
or
, 
ex
tre
m
e,
 u
nk
no
w
n.
 T
hi
s 
da
ta
 w
as
 o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l m
ed
ic
al
 re
co
rd
s.
 
O
rd
in
al
, c
at
eg
or
ic
al
 
Al
l P
at
ie
nt
 R
ef
in
ed
 
D
ia
gn
os
is
 R
el
at
ed
 G
ro
up
 
(A
PR
-D
R
G
) R
is
k 
of
 M
or
ta
lit
y 
 
Th
e 
lik
el
ih
oo
d 
of
 th
e 
pa
tie
nt
 d
yi
ng
. R
is
k 
of
 M
or
ta
lit
y 
is
 a
ss
ig
ne
d 
to
 th
e 
pa
tie
nt
 a
t t
he
 ti
m
e 
of
 d
is
ch
ar
ge
 b
as
ed
 o
n 
th
e 
pa
tie
nt
’s
 d
ia
gn
os
es
 a
nd
 
pr
oc
ed
ur
es
 th
at
 w
er
e 
co
de
d 
fo
r b
illi
ng
 d
ur
in
g 
th
e 
ho
sp
ita
liz
at
io
n.
 T
he
re
 a
re
 
fiv
e 
ca
te
go
rie
s:
 m
in
or
, m
od
er
at
e,
 m
aj
or
, e
xt
re
m
e,
 u
nk
no
w
n.
 T
hi
s 
da
ta
 w
as
 
ob
ta
in
ed
 fr
om
 h
os
pi
ta
l m
ed
ic
al
 re
co
rd
s.
 
O
rd
in
al
, c
at
eg
or
ic
al
 
IC
U
 c
ar
e 
du
rin
g 
in
de
x 
ad
m
is
si
on
 
An
y 
ca
re
 in
 th
e 
in
te
ns
iv
e 
ca
re
 u
ni
t (
IC
U
) d
ur
in
g 
th
e 
in
de
x 
ho
sp
ita
l 
ad
m
is
si
on
 (y
es
/n
o)
; o
bt
ai
ne
d 
fro
m
 h
os
pi
ta
l e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s.
 
 
D
ic
ho
to
m
ou
s,
 
ca
te
go
ric
al
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